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Contagious bovine pleuropneumonia (CBPP) is a bovine bacterial disease of major 
economic importance in sub-Saharan Africa. Vaccination has been recommended to 
control the disease in endemic areas such as the Maasai ecosystems of Kenya and 
Tanzania; however, the currently used live attenuated vaccine has been reported to have 
poor vaccine safety and efficacy. To compare standard (current) and an improved 
(buffered) version of the live CBPP-vaccine, several epidemiological studies were 
carried out in Maasai cattle in Kenya between 2006 and 2008. Specifically, the aims 
were to estimate CBPP seroprevalence at herd and animal level; to identify risk factors 
for seroprevalence at both levels; to investigate the spatial distribution of 
seroprevalence; to compare post vaccination adverse events in cattle vaccinated with a 
standard and a buffered vaccine, and finally to compare efficacy of the two vaccines to 
induce seroconversion and to prevent development of clinical signs suggestive of CBPP. 
A cross-sectional study was carried out in 6872 cattle in 175 randomly selected 
herds from Loita and Mara divisions. A competitive ELISA revealed that 85% of the 
herds in the area had at least one seropositive animal and that seropositive herds were 
harbouring 11% seropositive cattle. A complement fixation test revealed that 46% of the 
herds had at least one seropositive animal and that seropositive herds were harbouring 
4% seropositive cattle. A multivariable logistic regression analysis of the seroprevalence 
indicated that previous vaccination against CBPP, a history of CBPP outbreaks in the 
herd, animal age and the location of the herd in the division of Mara were positively 
correlated to seroprevalence. To investigate the observed difference in herd 
seroprevalence between the two divisions further, a spatial analysis was conducted. A 
SatScan test revealed clusters in Mara in areas identified by veterinary personnel as 
CBPP ‘hot spots’. A logistic regression using spatial information identified that location 
in the midland agro-ecological zone or close to a river and vaccination were positively 
associated with seroprevalence. 
To compare safety and efficacy of a standard and a buffered vaccine, two cohorts 
of approximately 40,000 cattle were used. The study showed that within 100 days post 
vaccination, 6.2 cattle per 1000 vaccinates developed adverse events, 4.1 of which were 
specifically attributable to vaccination and ranging from swelling of the tail to the tail 
sloughing off. This study revealed a slightly higher incidence of adverse events in cattle 
vaccinated with the buffered vaccine compared to the standard vaccine. A comparison of 
the efficacy of the two vaccines revealed that cattle vaccinated with the buffered vaccine 
had higher odds of seroconversion and lower odds of developing symptoms of CBPP, 
three and twelve months post vaccination respectively.  
The epidemiological studies conducted clearly show wide spread seroprevalence 
in the Maasai cattle. Given the (spatial) heterogeneity observed, control measures should 
probably be targeted in areas of increased risk (clusters). However, positive association 
of vaccination and seropositivity call for better diagnostics tests that can differentiate 
vaccinated from infected animals. Vaccination with buffered vaccine resulted in 
increased seroconversion, decreased clinical signs indicative of CBPP post vaccination 
and low seroprevalence post ‘outbreak’. Nevertheless, the increase in adverse events 
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Chapter 1 – General introduction 
 
1.1 Contagious bovine pleuropneumonia 
Contagious bovine pleuropneumonia (CBPP) is a transboundary cattle disease of major 
economic importance at herd and national levels. Annual losses amounting to €30.1 
million were estimated in a recent study of the economic impact of CBPP in 12 
endemically infected sub-Saharan African countries  (Tambi et al., 2006). These losses 
were attributed to mortality and reduction in beef and milk production and draft power. 
Further losses were attributed to reduced fertility and lost market opportunities due to 
trade bans  (Karimuribo et al., 1997; Rweyemamu and Benkirane, 1996). 
 
1.2 Causative agent  
1.2.1 Classification and general characteristics  
Mycoplasma mycoides subspecies mycoides Small Colony (MmmSC) is the causal agent 
of contagious bovine pleuropneumonia. It is an extra-cellular pathogen that lives in close 
association with the host cells. The organism is capable of self-replication, has a genome 
size of 1,211 kb and lacks a cell wall  (Westberg et al., 2004). MmmSC shares many 
biochemical, immunological and genetic properties with six other mycoplasmas grouped 
under the so-called Mycoplasma mycoides cluster (Pettersson et al.., 1996). Other 
members of the cluster are Mycoplasma mycoides subsp. mycoides large colony, 
Mycoplasma capricolum subsp. capricolum, Mycoplasma capricolum subsp. 
capripneumoniae, Mycoplasma mycoides subsp. capri and Mycoplasma sp bovine group 
7. MmmSC belongs to the Class Mollicutes, Order Mycoplasmatales and Family 
Mycoplasmataceae. The Family Mycoplasmataceae contains two genera, Mycoplasma 
(urea negative) and Ureaplasma (urea positive)  (Nicolet, 1996). Sequence analysis and 
phylogenetic studies of the 16S ribosomal RNA (16S rRNA) genes have shown that 
mycoplasmas are closely related to the Bacillus-Lactobacillus-Streptococcus group, 




Mycoplasmas are highly host specific and adapted to a main host in which they are 
commonly pathogenic, but may colonize other hosts  (Nicolet, 1996). MmmSC, for 
example, is commonly found in cattle suffering from CBPP but has also been isolated 
from sheep suffering from mastitis and goats suffering from contagious caprine 
pleuropneumonia. It is not clear whether presence of MmmSC in sheep and goats was 
causally associated with the observed diseases (Kusiluka et al., 2000a; Srivastava et al., 
2000; Brandão, 1995). 
1.3 Mode of transmission 
CBPP is a lung disease primarily of cattle (Bos indicus and B. taurus), no wildlife 
reservoir has been reported (Provost et al., 1987). CBPP transmission is effected through 
exhalation of infectious aerosols from an infected animal and inhalation by a susceptible 
animal. The main reservoir of MmmSC infection is cattle, from which bacteria have been 
isolated during the course of clinical disease  (Kusiluka et al., 2000b) and after clinical 
recovery  (Windsor and Masiga, 1977b). Bacteria have been isolated from nasal swabs 
and sequestra. Trans-placental transmission has been suggested following isolation of 
MmmSC from the foetus of an infected dam  (Masiga et al., 1972; Stone et al., 1969). In 
addition, MmmSC has been isolated from urine of acutely diseased cattle, with titres 
ranging between 102 and 108 organisms per millilitre of urine  (Scudamore, 1976). 
MmmSC has also been isolated from semen and sheath washings of two bulls  
(Gonçalves, 1994). The importance of infected urine or semen in the natural 
transmission of CBPP is unknown. Transmission through fomites and contaminated 
fodder has been suggested under experimental conditions  (Windsor and Masiga, 1977a). 
Although water buffaloes are susceptible to CBPP, transmission of CBPP from buffaloes 
to cattle has never been reported. 
1.4 Disease manifestation 
Following infection, the disease may take a variety of forms, depending on host 
susceptibility and virulence of the pathogen. Calves have been observed to get mild 
infections involving tendons and joints. Yearlings to three year-old animals show higher 
susceptibility than calves with lesions characterized by lung involvement  (Masiga and 
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Windsor, 1978). Compared to MmmSC isolated from CBPP outbreaks in Europe, 
MmmSC isolated from CBPP outbreaks in Africa and Australia have been reported to be 
highly pathogenic (Pilo et al., 2007; Nicholas et al., 1996). 
 
Peracute, acute, subacute and chronic forms of CBPP have been reported. Peracute cases 
may die without showing any clinical signs. Acute cases are characterized by rapid and 
severe pleurisy. Animals show dullness, anorexia and irregular rumination with high 
fever ranging from 40ºC to 42ºC  (Provost et al., 1987). Coughing is usually persistent 
and is slightly dry. When typical lesions develop, the signs become more pronounced 
with increasing frequency of coughing. Animals become prostrate or stand with back 
arched, head extended and elbows abducted due to laboured breathing. Peracute and 
acute cases are common during the early phase of an outbreak. Sub-acute and chronic 
forms occur in the majority of infected animals. In these forms, disease progression is 
slow and may take several weeks or even months before any clinical signs are observed. 
Articular localization of the pathogens is common in calves, causing lameness. 
Complications in calves may include endocarditis and myocarditis. In pregnant animals, 
abortion may occur. 
 
When CBPP is introduced into a fully susceptible cattle population, the disease usually 
results in high morbidity (up to 100%) and nearly 50% mortality  (Masiga et al., 1996). 
The incubation period is varied. Experimentally infected animals have shown clinical 
signs of disease (fever) after three weeks  (Hudson and Turner, 1963); or between 40 
and 57 days post challenge  (Wesonga and Thiaucourt, 2000). The incubation period 
after natural infection is not known. 
1.5 Diagnosis 
CBPP diagnosis relies on a combination of clinical examination, post-mortem and 
laboratory examination based on cultural methods and serological tests  (FAO, 2002). 
Protein and nucleic acid-based molecular techniques are also available (Bashiruddin et 
al., 1999; Gonçalves, 1994).  
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1.5.1 Clinical signs 
Diagnosis of CBPP on the basis of clinical signs is possible during the acute phase when 
signs are typical. Adult cattle will present persistent coughing and laboured breathing 
due to pleuropneumonia while calves show lameness as a result of arthritis (FAO, 2002; 
Provost et al., 1987). Symptoms are observed to decline in severity in proportion to the 
time that the disease has been present in the herd or region. No clinical signs are 
pathognomonic for CBPP. Therefore, it is important to eliminate other diseases 
presenting similar symptoms such as acute East Coast Fever or Ephemeral fever  (FAO, 
2002) from the differential diagnosis.  
1.5.2 Post mortem lesions 
Gross pathological lesions in the acute stage are characterized by fibrinous deposits on 
the parietal surfaces of lungs and distension of the interlobular spaces with straw 
coloured serofibrinous exudate  (Trichard et al., 1981). Lesions are usually unilateral, 
localised in the diaphragmatic lobe and present a characteristic marbling appearance 
(Masiga et al., 1996; Provost et al., 1987). Lesions are detectable on palpation, and upon 
incision, red and grey areas of hepatisation are revealed. In subacute cases, lesions are 
characterised by necrosis organized within lobules and interlobular septa and early 
sequestrum formation. Lesions in the chronic stage are characterised by well-defined 
sequestra surrounded by fibrous capsules. Adhesions, connecting thickened viscera and 
parietal pleura, are common (FAO, 2002; Amanfu et al., 2000; Nicholas et al., 1996; 
Trichard et al., 1981). 
1.5.3 Serological tests  
The Complement Fixation Test (CFT) and competitive Enzyme Linked Immunosorbent 
Assay (cELISA) have been prescribed by the World Organization for Animal Health as 
herd-level serological diagnostic tests. In challenge trials, CFT positive test results have 
been reported from 7 days  (Barber et al., 1970) and up to 5 months post infection  




Sensitivity (SE) of the CFT has been reported to vary with the stage of disease, being 
high during acute stages of disease when there is a high level of circulating complement-
fixing immunoglobulin (Amanfu et al., 2000; Barber et al., 1970). A SE of 98% was 
estimated in a study from an outbreak area in Botswana, in which post mortem lung 
lesions were used as a gold standard  (Amanfu et al., 2000). However, a much lower SE 
of 64% was estimated in a study from Italy, where due to an eradication programme the 
disease had very low prevalence  (Bellin et al., 1998). A SE of 67% has been reported 
from an outbreak in the Owambo Mangetti area of Namibia in 1981, in which lung 
lesions at slaughter were used as gold standard  (Trichard et al., 1981).  
 
A cELISA using a specific monoclonal antibody (117/5) has been developed and tested 
(Le Goff and Thiaucourt, 1998). No cross-reactions with other Mycoplasma species 
were reported during its development, and a relative SE of 96% and specificity (SP) of 
97% were reported when CFT results were used as gold standard  (Le Goff and 
Thiaucourt, 1998).  Studies on comparison of CFT and cELISA based on macroscopic 
lung lesions indicated that more than 95% of animals that had lesions were positive in 
both tests  (Amanfu et al., 2000). Animals vaccinated with live attenuated CBPP vaccine 
mount immune responses, which can be detected by CFT or cELISA (Geiger, 2003; 
Thiaucourt et al., 2000; Masiga and Mugera, 1973). Based on CFT and cELISA, 
immune responses following vaccination wane after three months  (Thiaucourt et al., 
2000). Seroprevalence studies in areas where vaccination has been carried out have 
indicated a poor agreement between CFT and cELISA  (Matua-Alumira et al., 2006).  
 
1.6 CBPP distribution 
The chronology of CBPP outbreaks and eradication in different countries has been 
reviewed (Masiga et al., 1996; Rweyemamu and Benkirane, 1996; Provost et al., 1987). 
CBPP was widespread in Europe in the 18th century due to uncontrolled cattle 
movements that were caused by wars, transhumance and trade. The disease was 
introduced into the USA, Australia, Asia and southern Africa in the 19th century by 
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importation of infected animals from Europe. East, Central and West Africa are believed 
to have been infected in the 19th century by cattle from India  (Provost et al., 1987).  
CBPP was eradicated from most of western Europe, the USA and Japan by the end of 
the 19th and beginning of 20th century through vigorous control efforts involving 
stamping out and strict control of animal movements  (Provost et al., 1987). Some foci 
of disease remained in Spain, Portugal and Italy and flared up again in the 1980’s and 
1990’s. However, effective control policies made eradication a success  (Regalla et al., 
1996). Australia succeeded in eradicating the disease in 1973 after the disease being 
present in the country for 100 years. The control strategy was based on vaccination, 
animal movement control and implementation of a slaughter policy, backed-up with an 
efficient surveillance system  (Newton, 1992). 
 
According to the OIE, between 2007 and 2008 CBPP was wide spread in 12 countries in 
Africa (http://www.oie.int/wahis/public.php?page=disease_status_lists as accessed on 
2nd April 2009). The countries were Uganda, Tanzania and Ethiopia in East Africa and 
Nigeria, Niger, Chad, Benin, Ghana, Burkina Faso, Togo, Democratic Republic of 
Congo and Angola in western and central Africa. CBPP had a zonal distribution as a 
result of CBPP control in countries such as Burundi, Namibia, Zambia, Kenya and Mali 
(Thomson, 2005). There are African countries that seem to have managed to eradicate 
CBPP; Zimbabwe, for instance, last reported the disease in 1904 and South Africa in 
1924. Botswana was officially declared free of CBPP in 2008 and Sénégal declared 
itself provisionally free of disease according to the OIE pathway of declaration of CBPP 
freedom (http://www.oie.int/eng/info/en_ppcb.htm accessed on 6th April 2009). 
 
1.7 CBPP Control strategies 
The USA, Japan and Western Europe managed to eradicate the disease through stamping 
out coupled with strict animal movement control (Masiga and Domenech, 1995; Provost 
et al., 1987). Recently, Botswana managed to control and eradicate CBPP through 
stamping out  (Amanfu et al., 1998). However, stamping out may not be economically 
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feasible in endemic African countries and vaccination is the most frequently used 
control strategy in combination with animal movement control. To be effective, 
vaccination must be repeated initially at short intervals and thereafter annually over 3-5 
years (FAO, 2002). CBPP vaccination was initially (1920’s to early 1970’s) based on 
broth T1 vaccine Davies et al., 1968; Gilbert et al., 1970) which was later replaced by 
freeze-dried live attenuated MmmSC vaccine T1/44 vaccine (OIE, 2008). A streptomycin 
resistant variant (T1sr) was developed and used in combination with Rinderpest vaccine 
(Rweyemamu et al., 2000). Re-assessment of efficacy of two predominant vaccine 
strains (T1/44 and T1/sr) by means of a challenge trial was carried out following 
vaccination failures in Botswana (Thiaucourt et al., 2000). The challenge trial was 
carried out in Cameroon, Kenya, and Namibia to cover the genetic diversity that exists 
among the pathogenic strains from different geographic areas. Susceptible cattle were 
vaccinated with either vaccine containing the minimum dose of 107 viable MmmSC per 
dose, as recommended by the OIE (OIE, 2008). The efficacy varied from 33-67% 
regardless of the strain used. In a similar experiment, T1/44 provided higher protection 
(95%) than T1/sr (80.5%) in cattle vaccinated twice (Wesonga and Thiaucourt, 2000). 
Based on a number of controlled experiments, CBPP vaccine efficacy ranged from 40% 
up to 95% (Thiaucourt et al., 2000; Wesonga and Thiaucourt, 2000; Masiga and 
Windsor, 1978; Masiga and Windsor, 1974; Karst, 1972; Gilbert et al., 1970; Davies et 
al., 1968). Estimation of vaccine efficacy was based on the Hudson and Turner scoring 
system (Hudson and Turner, 1963). However, the method has not been used consistently 
and comparison of results across trials may not be meaningful (Mariner et al., 2006).  
Antibiotic treatment against CBPP is widely used. It is not part of any official control 
strategy due to suspicion that its use could facilitate developments of sequestra, increase 
the number of carrier animals, increase development of resistant strains, and mask the 
occurrence of clinical disease  (Provost et al., 1987). Masking of clinical disease will 
make diagnosis difficult, which may contribute to unrecognized infections and CBPP 
transmission. Nevertheless, antibiotics are widely used in pastoralist communities 
(Mariner et al., 2006; Twinamasiko et al., 2004; Msami et al., 2001). At a meeting of 
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international experts organized by FAO in 2003 it was recommended that chemotherapy 
be reconsidered for CBPP control. Both in-vivo and in-vitro studies demonstrating 
usefulness of antibiotics for treating CBPP have been reported (Hübschle et al., 2006; 
Twinamasiko et al., 2004; Yaya et al., 2004; Ayling et al., 2000). In an in-vitro 
experiment, tilmicosin, danofloxacin, oxytetracycline, florfenicol and spectinomycin 
were found to be effective against a variety of strains of MmmSC isolated from CBPP 
cases that had occurred in Africa and Europe (Ayling et al., 2000). In a study carried out 
in Namibia, it was demonstrated that naïve animals kept in-contact to denofloxacin 
treated animals with CBPP had significantly fewer lesions, were less likely to die and to 
develop clinical disease than naïve animals kept in-contact to untreated animals with 
CBPP. In the same study, MmmSC was isolated from a limited number of in-contact 
controls kept with the treated animals suggesting low spread of infection  (Hübschle et 
al., 2006). In a different trial, long-acting tetracycline was demonstrated to be effective 
in limiting clinical severity of the disease but ineffective in the prevention of persistence 
of viable MmmSC in treated animals (Niang et al., 2007; Yaya et al., 2004). Thus, the 
direct effect of tetracycline on the individual is positive (less clinical damage), but the 
indirect effect on the population may be negative (masking of signs leading to 
transmission). 
Infection control methods act by reducing the effective reproductive number of the 
infectious agent in the population  (Tambi et al., 2006). The effective reproductive 
number is affected by contact between individuals, transmission probability per contact 
and duration of infectiousness. Animal movement control reduces the contact between 
infected and susceptible animals. Vaccination and treatment reduce susceptibility and 
infectiousness, respectively, at the individual level, thus reducing the probability of 
transmission per contact and reducing the prevalence of infection in the population.  
Because CBPP is a contagious disease, a reduction in prevalence will result in reduction 
in incidence thus further reducing prevalence in the population. 
For the purpose of implementing different control strategies, Kenya was divided into 
different zones and zonation has undergone revisions in 1982 and 1998 due to changing 
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disease situations (Wanyoike, 1999). In 1982, for instance, there were three disease 
categories; category A (infected areas), category B (areas of risk but not infected) and 
category C (clean). The control strategy was based on vaccination and animal movement 
control in category A, animal movement control without vaccination in category B and 
no CBPP control measures in category C. In 1998, changes in the disease situation led to 
the formation of three alternative zones, i.e. zone I, II and III representing CBPP clean, 
recently infected and endemic areas respectively. In CBPP clean areas (Zone I), 
surveillance was carried out in all slaughter facilities accompanied by zoosanitary 
measures at livestock markets, borders check points and stock routes (Wanyoike, 1999). 
Disease control strategies for zone II were disease surveillance and vaccination in the 
event of a confirmed outbreak. In addition, zoosanitary measures were enforced. For 
zone III, the strategy was intensive vaccination and zoo-sanitary control measures.  
Wanyoike (1999) mapped the disease situation in Kenya over a period of ten years 
(1989-1998) based on suspected and confirmed CBPP outbreaks This information was 
synthesized and led to revision of zoning into infected, surveillance, buffer and clean 
zones (Kairu-Wanyoike et al., 2004). Guidelines for disease surveillance are outlined in 
the OIE Terrestrial Animal Health Code. Based on the current version, surveillance for 
disease involves reporting any signs of disease by veterinary services or livestock 
owners and an active programme of examination of a statistically determined sample 
from the host population in order to detect clinical signs or other indications of the 
occurrence of disease or transmission of infection 
(http://www.oie.int/eng/normes/mcode/en_chaptre_1.11.8.htm accessed on 9th July 
2009). Suspicion of disease should be followed by actions such as submission of 
samples for laboratory confirmatory tests and enforcement of quarantine. Zoosanitary 
measures include issuance of cattle movement permits. It is recommended that cattle 
from infected areas should only be permitted to move to designated abattoirs. Intensive 
vaccination implied annual vaccination of all animals in the area with a vaccine 





1.8 CBPP in Maasai ecosystem of Kenya and Tanzania 
There is no report of when the disease was first confirmed in Kenya, though it appears 
that there were suspected deaths as a result of pleuropneumonia-like disease in 1901 
around Nairobi. Since then, the disease has spread widely in the country due to 
uncontrolled movement of infected animals (Kariuki, 1971). CBPP in the Maasai 
ecosystem was first reported in 1919 and it was widespread in Kenya by 1920 whereas 
in Tanzania the disease was confined in the Kenya-Tanzania Maasai ecosystem 
(Lwebandiza, 1969; Kariuki, 1971). By the 1970s, the disease was controlled in most 
parts of Kenya through quarantine, animal movement control and vaccination. However 
Maasailand (Kajiado and Narok) and other pastoralist communities remained as enzootic 
areas (Kariuki, 1971), maybe because of difficulty in controlling animal movement.  The 
disease seems to have been cleared from the Maasai ecosystem, possibly through well-
coordinated combined Rinderpest-CBPP vaccination programmes, between 1975 and 
1982 when the area was categorized as clean area (Wanyoike, 1999).  Re-emergence of 
the disease in the Maasai ecosystem of Kenya in 1990s did not only affect the Kenyan 
side but the disease was also re-introduced to the Maasai ecosystem of Tanzania due to 
illegal cattle movement (Msami et al., 2001). Control of animal movement is an 
important part of CBPP control strategies. Of the outbreaks traced in Kenya for example, 
33.9% were found to be related to cattle movements (Wanyoike, 1999). Intensive 
vaccination, movement control and surveillance were still the major recommended 
control methods that were given priority when the disease re-emerged in the 1990s 
(FAO -EMPRES, 1995). The disease has not been cleared from Maasai land and the area 
is currently categorized as infected (Wanyoike-Kairu et al, 2004).  
 
1.9 Aim and objectives of the study 
CBPP control through vaccination has been unsatisfactory due to practical difficulties 
that range from inability to obtain uniform and consistent vaccine coverage to 
uncontrolled animal movement, poor vaccine efficacy and safety and poor vaccine 
stability post reconstitution (Thomson, 2005; Thiaucourt et al., 2000; Wanyoike, 1999; 
Revell, 1973). Annual vaccination coverage between 1989 and 1998 in endemic districts 
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of Kenya ranged from 20 to 60%  (Wanyoike, 1999). In Nigeria, overall vaccination 
coverage of 9.7% was observed between 1988 and 1999  (Aliyu et al., 2000). Average 
annual CBPP vaccination coverage in endemically infected African countries between 
1998 and 2003 ranged from 0.8 to 48%  (Thomson, 2005) which is far below the 
recommended 100%  vaccination repeated initially at short intervals (6 months) then 
annually for 3-5 years.  
Field trials for estimation of vaccine efficacy have not been reported. However, based on 
field observations in the 1990s, it was reported that CBPP vaccines based on T1/44 were 
not able to contain outbreaks (Amanfu et al., 1998; Thiaucourt et al., 2000). Low T1/44 
vaccine efficacy was suggested to be caused by sub-optimal titres attained during 
vaccine production that did not allow for losses during lyophilisation, storage and 
transport  (Rweyemamu et al., 1995). Vaccine culture viability was affected by a drop in 
pH following metabolism of glucose in Gourlay’s growth media by MmmSC (Windsor, 
1978). Experiments have shown that inclusion of a buffer system based on 4- (2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) in standard Gourlay’s culture 
media was sufficient to prevent the drop in pH  (Waite and March, 2001). 
 
The current study was part of a Wellcome Trust-funded project (Grant No 075804) 
aimed at developing and validating new technologies for control of CBPP in East Africa. 
The project was devoted to comparing safety and efficacy of a standard and a buffered 
vaccine and to estimating socio-economic effects of CBPP control by vaccination. In 
addition, the project was devoted to developing and evaluating a genetically modified 
vaccine. This dissertation focuses on CBPP epidemiology and vaccine safety and 
efficacy aspects of the Wellcome Trust funded project. Two vaccines, a standard vaccine 
(Contavax®) currently used in Kenya for control of CBPP and a buffered vaccine  
(March, 2004) were compared. The buffer system in the new vaccine improves and 
prolongs viability of the MmmSC in the vaccine (Waite and March, 2001), and the 
higher titre of viable organisms in comparison with the standard vaccine is expected to 





 Several epidemiological studies were carried out in the Maasai cattle of south-western 
Kenya between 2006 and 2008, including evaluation of seroprevalence before 
vaccination to establish a baseline and to identify risk factors for CBPP. Specifically, the 
aims of my work were 
 
i. Estimating CBPP seroprevalence at herd and animal level (Chapter 2) 
ii. Identifying risk factors for seroprevalence at both levels (Chapter 2) 
iii. Investigating the spatial distribution of seroprevalence at herd level (Chapter 
3) 
iv. Identifying and quantifying adverse events post vaccination (Chapter 4) 
v. Comparing post vaccination adverse events in cattle vaccinated with a 
standard and a buffered vaccine (Chapter 4), and finally, 
vi. Comparing efficacy of the two vaccines to prevent development of clinical 
symptoms of CBPP and to induce seroconversion (Chapter 5). 
 
The final chapter of my dissertation (Chapter 6) is devoted to an integrated discussion of 
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Chapter 2 - CBPP seropositivity and associated risk factor 
study in the Maasai ecosystem of south-western Kenya  
 
Abstract 
A cross-sectional study was carried out aimed at estimating the seroprevalence of 
contagious bovine pleuropneumonia (CBPP) in the Maasai ecosystem of south-western 
Kenya, and at identifying risk factors associated with seroprevalence at herd- and animal 
level. The study involved 175 randomly selected herds in Mara and Loita divisions. 
Based on competitive Enzyme Linked Immunosorbent Assay (cELISA), 149 (85%) 
herds had at least one seropositive animal; based on Complement Fixation Test (CFT), 
79 (45.7%) herds had at least one seropositive animal. Based on cELISA, animal-level 
seroprevalence was 11.2% and 9.7% for animals (n = 5963) from seropositive herds (n = 
149) and animals (n = 6872) from all herds (n = 175), respectively. Based on CFT, 
animal level seroprevalence was 4.2 % and 1.9% for animals (n = 3170) from 
seropositive herds (n = 79) and animals from all herds, respectively.  
 Identification of risk factors associated with seroprevalence was carried out using 
multivariable logistic regression with correction for clustering at herd level in animal-
level models. Univariable and multivariable analysis for herd-level seroprevalence 
identified CBPP vaccination as significant risk factor in models based on cELISA or 
CFT results, with higher risk for higher number of vaccinations. In the herd-level model 
based on cELISA results, the number of animals tested and division or identification, by 
herders, of trypanosomosis as one of the most important diseases affecting their animals, 
were also significant. The latter two variables were highly correlated. The animal-level 
model based on cELISA showed that division, listing of trypanosomosis among 
important diseases and age of the animal were significant risk factors for seropositivity, 
as well as an animal being old enough to have been present at the time of the most recent 
CBPP vaccination or outbreak. Age-related results suggest that age may be a proxy for 
accumulated exposure, even when known exposure is accounted for. In the model based 
on CFT, being old enough to have been present during the most recent CBPP outbreak 
was the only significant risk factor. The current study shows that agreement between 
cELISA and CFT test results at animal level was low, and that seroprevalence was 
significantly higher in herds reporting vaccination. These findings suggest that CBPP 
diagnosis and identification of risk factors is challenging in areas where vaccination is 
being practiced. There is a need therefore for research to develop better diagnostic tests, 
specifically tests that can differentiate vaccination from infection/disease when 





A number of epidemiological studies have been conducted to determine CBPP 
prevalence in endemic countries in sub-Saharan Africa. Using the Complement Fixation 
Test (CFT), a seroprevalence of 10.5% was reported based on individual samples 
submitted to the Central Veterinary Laboratory in Kenya between 1988 and 1998  
(Wanyoike, 1999). In a separate cross-sectional study of 457 samples collected from 
Kajiado District in Kenya (Matua-Alumira et al., 2006), CBPP seroprevalences of 
14.3% and 4.9% were estimated based on competitive Enzyme Linked Immunosorbent 
Assay (cELISA) and CFT, respectively. In an abattoir serological survey conducted in 
CBPP-endemic areas of Nigeria, cELISA and CFT seroprevalences of 32% and 27% , 
respectively, were observed (Aliyu et al., 2003). In three separate cross-sectional 
studies, CBPP seroprevalence and risk factors in pastoral systems of Sudan (Zessin et 
al., 1985; McDermott et al., 1987) and Ethiopia (Bonnet et al., 2005) were described. 
However, such analyses have been lacking for the Maasai ecosystem, which is a 
transhumant pastoral system. Animals kept under pastoral systems are continuously at 
risk of contracting infectious diseases such as CBPP because of uncontrolled movement 
and extensive mixing in grazing, watering and saltlick areas. This is exacerbated by 
livestock markets, migration in search of pastures and water during dry seasons, and 
dowry or gift exchanges and other cultural practices  (Zessin et al., 1985; Mariner et al., 
2006). 
 
The CFT and cELISA are the OIE prescribed herd level tests for CBPP and they are said 
to have specificity of 98% and 99.9%, respectively; Sensitivity for both tests is said to be 
about 70%. Vaccinated animals are seronegative by CFT within 3 months post 
vaccination (http:www.oie.int/eng/norms/mmanual/2008/pdf/2.04.09_CBPP.pdf as 
accessed on 9th July 2009). According to Thiaucourt and colleagues (2000), immune 
responses measured by cELISA following vaccination also wane after 3 months  
(Thiaucourt et al., 2000). No guidelines have been given by the OIE with regard to 
interpretation of CFT and cELISA results when both tests are performed on the same 
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samples. Depending on the intention of testing, parallel or serial interpretation can be 
carried out. Parallel interpretation, i.e. a sample is considered positive if at least one of 
the tests is positive, could be used when the intention is to increase sensitivity at the cost 
of specificity. Conversely, serial interpretation, i.e. a sample is only considered positive 
if both tests are positive, would increase specificity at the cost of sensitivity. (Dohoo et 
al, 2003).  
   
The availability of epidemiological data on CBPP in Maasai cattle would assist in the 
development of surveillance and control strategies specific for this herding system. The 
objective of this study was therefore to conduct an epidemiological survey of CBPP in 
the Maasai ecosystem of south western Kenya. Specifically, the study aimed to: 
 
i. Estimate CBPP seroprevalence at herd and individual animal levels 
ii. Identify risk factors associated with CBPP seroprevalence at herd and 
individual animal levels 
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2.2 Materials and methods 
2.2.1 The study area 
The study was carried out in the Loita and Mara divisions of Narok District, which is 
situated in the Rift valley province of south western Kenya (Figure 2.1). The district lies 
between 34˚45’E and 36˚00’E and 0˚45’S and 2˚00’S  (Serneels et al., 2001) and 
borders the Loliondo district of the United Republic of Tanzania to the south, Nakuru to 
the north, Kajiado to the east, and Transmara and Bomet to the west. The district 
occupies 15,098 km2 and its population is estimated at 365,750 based on a 1999 census 
(www.statoids.com accessed on 6th April 2009). The area experiences bimodal rainfall 
with long rains between March and May and short rains between October and 
December. On average, the area receives between 500-800 mm rain annually, with high 
local variations. The rains are unreliable and evaporation levels are high  (Jaetzold and 
Schmidt, 1983). 
 
Mara and Loita divisions are inhabited predominantly by Maasai people of two 
ethnicities, the Purkos and Loitas, whose livelihoods depend largely on pastoral and 
agro-pastoral activities. Maasai cattle and small ruminants are routinely confined to 
paddocks known as bomas overnight, with kids and calves being accommodated in the 
same huts (manyatas) as their owners. During the dry season, migrations involving cattle 
more than 2 years old are usually carried out by the morani (young warriors) under 
supervision of elders, whilst the milking herd, sheep and goats remain at the main 
homestead. The study area was selected because it falls within a nationally designated 
infected zone  (Wanyoike-Kairu et al., 2004) and has a history of CBPP outbreaks (H. 
Kiara, personal communication, 2008).  
 
The current field study was carried out between July and September 2006. Although this 
is normally the dry period, for this particular year there was prolonged rainfall. As a 




Figure 2.1: Map indicating location of the study district in Kenya  
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2.2.2 Selection of participants 
A cross-sectional survey was carried out on the basis of two sampling frames. One 
sampling frame consisted of herders registered with the Ilkerin-Loita integral 
development programme for Loita Division. A similar sampling frame, with herders’ 
names, locations and sub-locations (these are official administrative units) and types and 
numbers of animals, was developed for Mara Division, where a comprehensive register 
for herders was not available. OIE recommends the use of CFT or cELISA as herd-level 
test and suggests that sample size should be adjusted to compensate for low sensitivity 
of the tests (http://www.oie.int/eng/normes/mcode/en_chapitre_1.11.8.htm; last accessed 
14th July 2009). The sample size was calculated using Win Episcope 2.0 
(http://www.clive.ed.ac.uk) based on 95% confidence level, 5% absolute precision and 
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an expected prevalence of 5% at herd level. The number of herds to be sampled in each 
division was determined by proportional allocation based on number of animals in the 
area. Within each division, sub-locations were purposively selected to attain a wide 
geographical representation. Within sub-locations, participants were selected randomly 
from lists of herders. Sampling units comprised single herds and the sample size for 
detecting at least one positive animal within the herd was calculated on the basis of an 
expected within-herd prevalence of 10%, with 95% confidence level. The 
seroprevalence used was within the range found in the literature (Mariner et al., 2006; 
Matua-Alumira et al., 2006; Zessin et al., 1985). For the purposes of the study, a herd 
was defined as the animals kept in one enclosure. Animals in a herd could therefore 
belong to more than one herder. For each herd, an effort was made to include animals of 
different ages and both genders.  Herders that were included for the current study had 
not reported CBPP vaccination at least six months prior to the study in order to avoid 
seropositivity resulting from vaccination.  
Fifty-four of the randomly selected herders were excluded from the study because they 
had migrated, their cattle had been vaccinated within the past six months or because 
their animals shared a boma with another selected herder. Replacements were selected 
using residual random numbers. If animals of a replacement herder were part of the 
same boma, another herd was chosen from the same vicinity. 
2.2.3 Questionnaire development, pre-testing and interviews 
A questionnaire was designed to determine herders’ knowledge on livestock diseases 
(particularly CBPP control measures), livestock contacts and movements and herd 
dynamics. One herder was interviewed for each cattle enclosure. The questionnaire 
contained mostly closed-ended (categorical) questions to facilitate data analysis, 
minimize variation and improve precision of responses. Six interviewers fluent in 
English and Maasai were recruited and trained on use of the questionnaire as a method 
of data collection. Based on the recommendation that pre-testing should be performed in 
the same population in which the actual study will be carried out  (Thrusfield, 2005), 
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pre-testing of the questionnaire was carried out in Sekenani sublocation of Mara division 
between June 26 and July 1, 2006. The performance of the questionnaire was evaluated 
in terms of the time taken to complete the interviews and the ambiguity, mutual 
exclusivity and relevance of questions, and modifications were made as necessary. The 
duration of interview was more than three hours during pre-testing. After modification 
of the questionnaire, the actual interviews took approximately 70 minutes. The 
questionnaire was developed, evaluated and carried out in partnership with S. Wanyoike, 
University of Reading, UK, as part of a multidisciplinary Wellcome-Trust funded 
project. The questionnaire (Appendix i.) had three sections. The first section was a 
general one with herders’ information, while the second detailed important livestock 
diseases, CBPP occurrence and control measures. The third section focused on herd 
demography and cattle contact structure and movements. 
Face to face interviews were carried out between July and September 2006 in all 
selected herds. On arrival at the relevant households, interviewers introduced themselves 
and outlined the project objectives to the household head before requesting permission 
to interview. The interviews were carried out in the Maasai language and the responses 
back-translated into English by the interviewers.  
2.2.4 Sera collection and analysis 
Four bleeders were recruited and trained on the bleeding protocol to ensure high 
standards in handling and labelling of samples. For each selected animal, body condition 
was recorded based on a nine-unit scoring system and scores were collapsed into three 
categories (good, fair or poor condition). About eight ml of blood was drawn from the 
jugular vein using sterile 21 gauge needles (Becton Dickinson Vacutainer Systems, 
Plymouth, UK) and 9 ml plain vacutainer tubes (Greiner Bio-One North America inc, 
USA), which were labelled with unique herd and animal numbers. Clotted blood was 
centrifuged at 800g for 5 minutes using a portable centrifuge (MSE, UK) and sera were 
collected into serum tubes (MS Kay and Company, New Delhi, India). These were 
stored in a refrigerator for a maximum of 7 days before being transferred in cooler boxes 
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to Kenya Agriculture Research Institute (KARI), Muguga, Kenya, where they were kept 
at frozen at -20°C until analyzed. 
The serum samples were analysed using the cELISA kit described by Le Goff and 
Thiaucourt (1998) developed and supplied by CIRAD-EMTV. Briefly, two plates were 
used for each sample run, the U-bottom (dilution) and MmmSC precoated plates 
(MmmSC = Mycoplasma mycoides subsp. mycoides Small Colony, the causative agent 
of CBPP). For the plate layout, columns A1-H1 and A2-H2 were used for control 
samples while test samples were in wells A3 (sample no 1) to H12 (sample no 80). Each 
of the plates had a strong positive control sample dispensed in wells B1, B2, C1 and C2; 
weak positive control sample in wells D1, D2, E1and E2; negative control sample in 
wells H1 and H2. Wells A1 and A2 were for conjugate control while F1, F2, G1, and G2 
were for monoclonal control samples. 
100 µl of dilution buffer was dispensed into all wells of the dilution plate (Greiner, UK). 
Then 11 µl of each test sera or control samples were added into wells to give roughly a 
1:10 dilution. 110 µl of monoclonal antibody (mab) 117/5 anti-MmmSC (diluted 1:120 
in kit dilution buffer) was added to all the wells except A1 and A2 where 110 µl of kit 
dilution buffer was added. 100 µl of the contents of each well was transferred into the 
corresponding wells of the MmmSC precoated plate. The plate was then incubated at 
37ºC for one hour with gentle agitation. The plate was then washed twice with kit wash 
buffer, after which 100µl of horseradish peroxidase-conjugated rabbit anti-mouse IgG 
(diluted 1:100 in kit dilution buffer) was added to each well and the plate incubated at 
37ºC for 30 minutes. After a further three washes with the kit wash buffer, 100 µl of 
TMB substrate (supplied with the kit as ready to use solution) was added and the plates 
were incubated at 37ºC for 20 minutes. The reaction was stopped by addition of 100 µl 
0.5M sulphuric acid; the plates were gently shaken to homogenize the coloured solution. 
The underside of plate was wiped and optical density (OD) of individual reactions was 
measured at 450 nm using a plate reader (PR2100, Sanofi, Pasteur diagnostic, USA). 




 PI= { (ODmab- ODtestserum)/ (ODmab- ODconjugate)} x 100%                         [1] 
 
ODmab is optical density for the monoclonal antibody; ODtestserum is optical density for 
the test serum; ODconjugate is optical density for the conjugate. All samples that showed a 
PI of 50% or higher were considered positive for CBPP  (Le Goff and Thiaucourt, 
1998).  
Serum samples were also analysed by CFT. Preparation for CFT commenced at least 
two days before the test was performed. Fifty ml of sheep blood was collected into 
graduated bottles containing an equal volume of Alsever’s solution and stored at 4ºC for 
at least 2 days before use. On the day of the test, the blood cells were pelleted at 700g 
for 10 minutes and washed three times with Veronal buffer containing calcium and 
magnesium (VCM), with 1 volume of sheep red blood cells (RBC) washed in 9 volumes 
of VCM. The RBC fraction was then reconstituted in VCM to make a 6% suspension. 
To this, an equal volume of haemolytic serum (BioMérieux, France) diluted at 14 µl in 
10 ml VCM was added to make 3% RBC suspension. The suspension was then 
incubated for a minimum of 30 min at room temperature, with gentle agitation to 
sensitize the RBC. Meanwhile, 10 µl of test sera were diluted in 90 µl of VCM buffer to 
make a 1:10 dilution in U-bottomed 96-well plates. 25 µl of the diluted sera was 
transferred to the corresponding well of the test plate. To each well of the test plate 25 µl 
of MmmSC antigen (KARI-Muguga) diluted at 1:40 in CVM buffer (titre of antigen is 
dependent on the batch), followed by 25 µl of complement (BioMérieux) diluted 1:20 in 
VCM buffer was added to each well. Plates were then incubated at 37ºC for 30 minutes 
with gentle shaking, after which 25µl of the sensitized sheep RBC suspension was added 
to each well. After a further incubation at 37ºC for 30 minutes with shaking, plates were 
held at 4ºC overnight and results were recorded the following day. Interpretation of the 
results was in line with recommendations of OIE. Scoring (1-4) was based on subjective 
assessment of the degree of haemolysis, as evidenced by settling of RBC. With complete 
inhibition of haemolysis (4), all the cells settle at the bottom of the well and clear 
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supernatant is seen, whereas in-complete haemolysis (1) results in no sedimented RBC 
and a red supernatant fluid. Samples that scored 1 or 2 at the 1:10 dilution were 
considered negative, while those with scores of 3 or 4 at this dilution were re-titrated to 
obtain end point titres. In titrations, a reading of 3 or 4 was considered positive.  
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2.2.5 Data analysis 
Models were developed to identify factors associated with CBPP seropositivity at herd 
and animal levels. Separate models were developed for cELISA and CFT tests. Model 
building was guided by a hypothetical causal diagram (Figure 2.2a and 2.2b) based on a 
literature review. A history of CBPP outbreaks or vaccination were considered as the 
primary factor that could result in positive test results  (Barber et al., 1970; Niang et al., 
2007; Marobela-Raborokgwe et al., 2003; Trichard et al., 1981). Transmission between 
herds is driven by contact structures such as mixing during grazing, at salt licks and 
watering points, and by mixing with animals brought back from market  (Mariner et al., 
2006; Zessin et al., 1985). Trypanosomosis causes immunosuppression, which may 
make animals more susceptible to disease or unable to mount a good immune response 
upon vaccination (Ilemobade et al., 1982). Age was used as a proxy measure of 
accumulated exposure (Boelaert et al., 2005). At individual animal level, it was 
hypothesised that poor body condition could be associated with CBPP, either as a cause 
of increased susceptibility to disease or as a result of disease. A herd was defined as test-
positive if at least one animal in the herd was test-positive and the herd-level model was 
corrected for number of animals tested per herd. The dependent variable at animal level 
was whether the animal was positive or negative for a given test. Two animal level 
models were developed; the first model included herds with at least one positive animal, 
based on the assumption that without presence of at least one seropositive animal, there 
would be no exposure to CBPP and hence no opportunity to identify risk factors for 
infection. In this model, seropositive test results were thought to be due to infection and 
not to vaccination, because herds that vaccinated in the past 6 months had been excluded 
from the study and vaccine titres are claimed to wane 3 months after vaccination. The 
second model included all herds, based on the idea that serostatus may not be an 
accurate indicator of exposure, and to allow for consideration of a possible impact of 
vaccination on serostatus. CBPP outbreak and trypanosomosis reports were based on 




Figure 2.2a: Hypothetical herd-level causal diagram for detection of contagious bovine 




 Bring back (from market) expresses if animals not sold at the market are brought back home (Yes/No) 
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Figure 2.2b: Hypothetical animal-level causal diagram for detection of contagious bovine 


























The animal level model was corrected for clustering of animals within a herd  (Twisk, 
2003) as in other studies (Boelaert et al., 2005; Schnier et al., 2004; Zadoks et al., 2001). 
 
Descriptive statistics and model analyses were performed using the STATA statistical 
package (Intercooled 8th version; StataCorp: Texas, USA). Univariable logistic 
regression analysis was performed using independent variables selected on the basis of 
the hypothetical causal diagram. The multivariable model was built by backward 
elimination with P value set at ≤ 0.10 for retention in the model. Cross tabulations were 
carried out between independent variables to analyze interdependence among variables 
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at herd level. Animal-level models were built in the same manner as herd models but the 
final multivariable model was based on logistic mixed-effect regression with herd 
included as random effect. The general equation is given by: 
 
 logit (p)=β0+ ∑βiXi+ bj + ε;       [1] 
 
where p = outcome (positive or negative test results for cELISA or CFT; separate 
analyses were performed for the results from each diagnostic test); β0 = intercept; βi = 
regression coefficient for risk factor i; Xi = value of risk factor i; bj = random effect for 
herd j included only in the animal model; ε = error term. Regression coefficients were 
the natural logarithm of the odds ratio  (Dohoo et al., 2003). All tests were two tailed 
and a P value <0.10 was considered significant. 
The approximate attributable fraction (AF) was estimated for primary factors of interest 
i.e. vaccination and outbreak, using a general equation: 
 AF= (OR-1)/OR       [2]                        
where OR = odds ratio, based on the assumption that there is causal relationship  (Dohoo 
et al., 2003). 
Herd specificity (HSp) of 65% was estimated based on cELISA specificity of 99%. An 
HSp of 42% was estimated based on CFT specificity of 98%. The HSp was estimated 
based on the general equation: 
 HSp = Spn        [3] 
where n = median number of animals tested (43), Sp= specificity of individual test; 0.99 
for cELISA and 0.98 for CFT. The latter was estimated based on 33,000 sera from 
healthy herds that had been tested in Italy (Bellin et al., 1998). 
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 Model diagnostics were based on the detection of herds with undue influence on the 
model. Each herd was dropped from the animal model and the model was re-run to 
observe the changes on the estimates  (Schnier, 2004). Model diagnostics were 
performed using the SAS statistical package (SAS 9.1; SAS Institute Inc., Cary, NC, 
USA). 
Agreement of the cELISA and CFT animal-level results was assessed using the Kappa 
statistic  (Dohoo et al., 2003). 
 
Risk factors and categorization of variables that were considered for inclusion in the 





Table 2.1: Description of variables included in the models for identification of risk factors for 
contagious bovine pleuropneumonia 
 
Dependent variable Description 
Age 1: ≤1 yr; 2: >1 and ≤2 years; 3: >2 and ≤ 3 years; 4: >3 yrs 
Bring back from market Animals not sold at the market brought back home (Yes/No) 
Brought in Total number of animals brought into the herd in the past 12 
months through purchase, gifts and dowry 
Body condition Body condition scores (1: good; 2: fair; 3: poor) 
CBPP outbreak CBPP outbreak reported in the past 10 years (Yes/No) 
CBPP outbreak risk Reflection of an animal being old enough to have been present 
during last CBPP outbreak (0: absent; 1: present ) 
CBPP outbreak number Number of years in which CBPP outbreak in the herd has been 
observed by herder in the past 10 years (1: none; 2: one; 3: 
more than one) 
CBPP vaccination CBPP vaccination carried out in the past 10 yrs  (Yes/No) 
CBPP vaccination risk Was the animal old enough to have been present during the last 
CBPP vaccination (0: no; 1: yes) 
CBPP vaccination 
number 
Number of years in which CBPP vaccination was carried out in 
the past 10 years (1: none; 2: one; 3: more than one) 
Division Administrative units (Loita and Mara) 
Gender Animal gender (1: male; 2: female) 
Herd size Herd size (1: ≤42 cattle; 2: 43 to 99 cattle; 3: ≥100 cattle) 
Mixing at grazing Number of herds mixing at grazing point (0: <10; 1: ≥10) 
Mixing at saltlick Number of herds mixing at salt lick point (0: ≤5; 1: >5) 
Mixing at water Number of herds mixing at water point (0: ≤5; 1: >5) 
Number of animals 
tested 
Number of animals tested per herd (centred at 39 animals) 
Time since last CBPP 
outbreak 
2006 minus year of last CBPP outbreak expressed in years (1: 
≤1; 2: 2 ; 3: 3 to 10; 4: not experienced in last 10 years) 
Time since last CBPP 
vaccination 
2006 minus year of last vaccination expressed in years (1: ≤1; 2: 
2 ; 3: 3 to 10; 4: not experienced in last 10 years) 





 2.3 Results 
2.3.1 Study population 
In total, 179 herders were interviewed but complete data was available for only 175 of 
these, i.e. 132 from Mara and 43 from Loita. Herd size ranged from 6 to 450 cattle with 
a median of 75. The majority of herders (81%) reported vaccinating against CBPP in the 
past ten years, during which time CBPP outbreaks were reported by 42% of herders. The 
majority of herders had brought in animals through purchases, gifts or dowry in the year 
preceding the study (Table 2.2). 
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Table 2.2: General characteristics of the study herds participating in a survey of contagious 
bovine pleuropneumonia seroprevalence in the Maasai ecosystem of south-western Kenya 
 
Variable Levels Herds (%) 
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In total, 6998 animals were bled from the 175 herds, with a range of 2 to 47 animals per 
herd and a median of 43. A subset of 6872 were analysed by both tests and included in 
the statistical analysis. The study sample was dominated by zebu animals in fair to good 
condition. Study animals ranged from 1 month to 16 years in age with a median of 3 
years (Table 2.3). 
 
Table 2.3: General characteristics of the study animals participating in a survey of contagious 
bovine pleuropneumonia seroprevalence in the Maasai ecosystem of south-western Kenya 
 
Variable Variable levels Number of cattle (%) 
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 Animal old enough to have been present at the time of most recent CBPP outbreak. 
2.
 Animal old enough to have been present at the time of most recent CBPP vaccination. 
3.




2.3.2 Herd level seroprevalence and univariable risk factor estimates 
based on cELISA and CFT 
 
Competitive Enzyme Linked Immunosorbent Assay (cELISA) 
Of the 175 herds, 149 (85%) had at least one animal that tested positive by cELISA. 
Herd seroprevalence was significantly higher in Mara than in Loita (P <0.01) and was 
also greater among herds that reported CBPP vaccination (90.1%) than those that did not 
(64.7%). A significant difference (P <0.05) was only observed between herds that had 
not vaccinated within the last 10 years and those that had vaccinated within the past 12 
months (Table 2.4). Eighty nine percent of herds that reported a previous CBPP outbreak 
and ninety percent of herds that reported CBPP vaccination had at least one cELISA-
positive animal. Seroprevalence estimates for herds that had vaccinated twice or more 
against CBPP were higher than for herds that vaccinated once but the difference was not 
significant. Increased time since last vaccination was associated with decreasing 
seroprevalence. Herd seroprevalence was higher in herds that brought in animals but the 
difference between these and herds that did not bring in animals was only significant in 
herds that brought in 10 or more animals (P < 0.10). 
 
Complement Fixation Test (CFT)  
Based on CFT, 79 of the 175 tested herds had at least one positive animal, resulting in 
herd-level seroprevalence of 45.7%. Herd seroprevalence in Mara was higher than in 
Loita, but the difference was not significant. Fifty percent of herds that reported a 
previous CBPP outbreak or CBPP vaccination had at least one CFT-positive animal. 
Point estimates for herd seroprevalence were lower for herds that did not report CBPP 
outbreaks or vaccination, but the difference was only significant for vaccination (P < 
0.05). Point seroprevalence estimates for herds that had vaccinated twice or more against 
CBPP were higher than for herds that had vaccinated once but the difference was not 
significant. Increased time since last vaccination was associated with decreasing point 
estimates for herd-level seroprevalence, but differences were non-significant. No other 
variables were significantly associated with CFT seroprevalence (Table 2.4). 
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Table 2.4: Herd-level estimates of risk factors predicting prevalence of contagious bovine pleuropneumonia based on cELISA and CFT 
results 
 










Odds Ratio (95% 
CI)
1 
Herds 175 85.1 (79.8-90.5) n/a 45.7 (38.3-53.2) n/a 
Bring back from market
2
 
   Yes 
















Brought in (number of animals)
 3
 
   0 
   1-9 






















   Yes 
















CBPP outbreaks number 
   0 
   1 






















   Yes 
















CBPP vaccinations number 
   0 
   1 






















   Mara 

















   ≤42 cattle; 
   43 to 99 cattle  





















Mixing grazing  
   <10 


















Mixing at salt lick  
   ≤5 
















Mixing at water  
   ≤5 
















Number of animals tested 
(centred) 
n/a n/a 1.1 (1.0-1.1)** n/a 1.0 (1.0-1.0) 
Time since last CBPP outbreak 
 ≤ 1 year 
   1 - 2 years 
> 2 and < 10 years 


























Time since last CBPP vaccination 
≤ 1 year 
   1 - 2 years 
> 2 and < 10 years 



























   Yes 


















 P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
2.
 Bring back (from market) express if animals not sold at the market are brought back home (Yes/No) 
3.
 Brought in express total number of animals brought into the herd in the past 12 months through purchase, gifts and dowry  
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Within cELISA seropositive herds, seroprevalence ranged from 2% to 40.5% (median 
8.6%). Based on CFT, seroprevalence within test positive herds ranged from 2.1 to 20% 
(median 4%) (Figure 2.3). For both tests, a bimodal distribution of within-herd 
seroprevalence was observed. A large number of herds had no or only one test-positive 
animal, shown as within-herd seroprevalence of 0 or 2%, respectively. The remaining 
herds had a wide range of within-herd seroprevalence with a mode at 5%, which would 
represent 2 or more seropositive animals, depending on the number of animals sampled 
within the herd. 
 
 
Figure 2.3: Frequency distribution of within-herd seroprevalence of contagious bovine 



























 2.3.3 Univariable animal level risk factor estimates based on cELISA and CFT 
 
Univariable model based on animals in cELISA positive herds 
Of the 6872 animals sampled, 5963 were from cELISA-positive herds and 688 were test 
positive, resulting in an animal-level seroprevalence of 11.2% in seropositive herds. The 
proportion of cELISA-positive animals was higher among female cattle and animals 
from Mara than among male cattle and animals from Loita, and seroprevalence 
increased with increasing age (Table 2.5). When age was evaluated within gender, 
increasing seroprevalence was associated with increasing age for both male and female 
cattle. Point animal seroprevalence estimates for animals with fair or poor body 
condition were higher than for animals with good body condition but the difference was 
only significant when comparison was made between animals with good and fair body 
condition (P < 0.10). The odds of being test positive were higher for animals of herders 
that listed trypanosomosis among the five major diseases affecting their livestock; this 
was also the case for animals old enough to have been present when the herd last had a 
CBPP outbreak (P <0.01) and for those belonging to herds that used CBPP vaccination 
(P <0.01). Odds of being seropositive was significantly higher in animals from herds 
that bring back animals that fail to sell at market and for animals from herds that mix 
with more than 5 herds at saltlick or 10 herds at grazing (P < 0.01). 
 
Univariable model based on cELISA results using all animals selected 
Seroprevalence of 9.7% was estimated based on animals from all herds. The risk factor 
estimates based on all animals are similar to estimates based on herds with at least one 
positive animal (Table 2.6). 
 
Univariable model based on animals in CFT positive herds 
Based on CFT, 3170 of the 6872 animals sampled were from positive herds; of these, 
133 were test-positive, resulting in an animal-level seroprevalence of 4.2% in 
seropositive herds. Animal-level CFT seroprevalence did not differ with division or 
CBPP vaccination status and was significantly higher among animals that were old 
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enough to have been present when the herd had last experienced a CBPP outbreak 
(6.0%) than for animals that were not old enough for that (3.5%). Animal seroprevalence 
was higher among animals in age categories 3 and 4 than in the age category 1 (Table 
2.5).  
 
Univariable model based on CFT results using all animals selected 
Animal-level seroprevalence of 1.9% was estimated based on 6872 animals from all 
herds. The odds of being test positive was significantly higher among animals in Mara 
division (P <0.10), for animals old enough to have been present when the herd last had a 
CBPP outbreak (P <0.01), and for animals old enough to have been present at the most 
recent CBPP vaccination (P <0.05). Mixing at water points was significantly associated 
with seroprevalence based on CFT (P <0.1) (Table 2.6). Other risk factor estimates were 




Table 2.5: Animal-level estimates of risk factors predicting prevalence of contagious bovine pleuropneumonia based on cELISA and CFT 
results (seropositive herds only) 
 
cELISA CFT Variable Number 
Seroprevalence 
(95% CI) 









Animals  5963 11.2 (10.4-12.0) n/a 3170 4.2 (3.5-4.9) n/a 
Age 
   1 month to 1 year 
   >1 to 2 yrs 
   >2 to 3 yrs 































Body condition  
   Good  
   Fair 

























Bring back from market
2
 
   Yes 



















CBPP outbreak risk 
   Yes 



















CBPP vaccination risk 
   Yes 




















   Mara 




















   Male 




















      1 month to 1 year 
     >1 to 2 yrs 
     >2 to 3 yrs 













1.7 (1.1-32)**  

































      >1 to 2 yrs 
      >2 to 3 yrs 







1.8 (1.1-3.1)***  












   ≤42 cattle 
   43 to 99 cattle  

























Mixing at grazing  
   <10 



















Mixing at salt lick  
   ≤5 



















Mixing at water  
   ≤5 




















   Yes 





















 P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
2.
 Bring back (from market) express if animals not sold at the market are brought back home (Yes/No) 
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Table 2.6: Animal-level estimates of risk factors predicting prevalence of contagious bovine pleuropneumonia based on cELISA and CFT 
results (all herds) 
 











Animals  6872 9.7 (9.0-10.4)  1.9 (1.6-2.3)  
Age 
   1 month to 1 year 
   >1 to 2 yrs 
   >2 to 3 yrs;  


























Body condition  
   Good  
   Fair 





















Bring back from market
2
 
   Yes 















CBPP outbreak risk 
   Yes 
















CBPP vaccination risk 
   Yes 

















   Loita  

















   Male 

















      1 month to 1 year 
      >1 to 2 yrs 
      >2 to 3 yrs  








































      >1 to 2 yrs 
      >2 to 3 yrs  

















   ≤42 cattle; 
   43 to 99 cattle  





















Mixing at grazing  
   <10 
















Mixing at salt lick  
   ≤5 
















Mixing at water  
   ≤5 

















   Yes 


















 P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
2.





2.3.4 Comparison of cELISA and CFT seroprevalence results 
The herd-level seroprevalence based on cELISA was higher than herd-level 
seroprevalence based on CFT for herds found in both Loita and Mara (P < 0.05). At 
animal level, cELISA seroprevalence was also higher than that based on CFT. Female 
cattle had a higher seroprevalence than male cattle based on cELISA but not based on 
CFT. Animal-level seroprevalence based on cELISA was significantly higher in animals 
old enough to have been present when the herd had last been vaccinating against CBPP, 
whilst that based on CFT was not. Increasing age was associated with increasing animal-
level seroprevalence as detected by cELISA but not CFT (Figure 2.4). Although animals 
from herders reporting trypanosomosis among important diseases had a higher 
seroprevalence based on cELISA (P <0.01), the association was not significant when 
examined with the CFT data. 
 
Figure 2.4: Age seroprevalence profile based on cELISA and CFT for detection of contagious 

































Of the tested samples, 6103 (89%) were negative for both tests and 32 (0.47%) were 
positive for both tests, whilst 101 (1.47%) were positive only for CFT, and 636 (9.25%) 
were positive only for cELISA. The observed test-agreement (89.3%) therefore barely 
exceeds the test-agreement expected based on chance (88.7%), resulting in a very low 
value for Kappa (0.05). 
2.3.5 Multivariable herd-level risk factor estimation 
Based on cELISA, vaccination was significantly associated with seroprevalence. 
Seroprevalence was also associated with division (Mara) and number of animals tested 
per herd (P < 0.05) (Table 2.7). Although time since last vaccination was significant 
using the univariable model, it was not so with the multivariable model. 
 
Herd CFT seroprevalence was also positively associated with vaccination. No other 
variables were significantly associated with seroprevalence (Table 2.7). 
 
Table 2.7: Herd-level multivariable model of risk factors predicting prevalence of contagious 
bovine pleuropneumonia based on cELISA and CFT results 
 





CBPP vaccination number 
   0 
   1 











3.4 (1.3-8.9)**  
Number of animals tested (centred)
3
  1.0 (1.0-1.1)** 1.0 (0.990-0.997) 
 
1.
 OR = odds ratio. P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
2.
 Division is significantly correlated with CBPP vaccination. When the variable Division is 
omitted from the model then both levels of vaccination number, i.e. once or more than once, 
become significant (P < 0.05) 
3. Number of animals tested was based on the difference between actual number tested from 








Cross-tabulation to assess interdependence between variables showed that reporting 
trypanosomosis as important disease and Mara division were positively correlated (P < 
0.01), as were trypanosomosis and reporting CBPP vaccination, and reporting 
vaccination and outbreak (Table 2.8).  
 
Table 2.8: Cross tabulation of herd variables included in models to predict seroprevalence of 
contagious bovine pleuropneumonia in the Maasai ecosystem of south-western Kenya1 
 










 26.77 2.94 1.28 
CBPP vaccination 
(Yes) 
0.000  18.06 22.32 
Trypanosomosis 
(Yes) 
0.087 0.000  24.81 
Division (Mara) 0.258 0.000 0.000  
1. Upper right half of the table shows Chi square statistic and lower left the P-values. 
 
In addition, Mara division was positively correlated with higher numbers of herds 
mixing at salt licks and watering points and increased number of animals brought-in 






















Table 2.8 (continued): Cross tabulation of herd variables included in models to predict 






 Upper right half of the table shows the Chi square statistic and lower left the p-values. 
2.
 Brought in expresses total number of animals brought into the herd in the past 12 months 
through purchase, gifts and dowry  
3.
 Bring back (from market) expresses if animals not sold at the market are brought back home 
(Yes/No) 
2.3.6 Multivariable animal-level risk factor estimation 
 
Multivariable model based on animals in cELISA positive herds 
Based on cELISA, increasing age and being old enough to have been present during the 
last CBPP vaccination were positively associated with seroprevalence (Table 2.9). When 
trypanosomosis was dropped from the model, division of origin was significantly 
associated with seroprevalence, whilst trypanosomosis was significantly associated with 
seroprevalence when division was dropped from the model.  
 
Multivariable model based on cELISA results using all animals selected 
Increasing age, being old enough to have been present during the last CBPP vaccination 
and being old enough to have been present during the last CBPP outbreak were 





















 6.63 0.58 4.08 4.93 3.18 
Mixing at 
salt(>5 herds)  




















0.08 0.17 0.07 0.55 0.23  
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with all animals (Table 2.10). In addition, animals from herds reporting trypanosomosis 
and animals from herds originating from Mara were positively associated with cELISA 
seroprevalence. 
 
Multivariable model based on animals in CFT positive herds 
Based on CFT, being old enough to have been present during last CBPP outbreak was 
significantly (P < 0.10) associated with seroprevalence (Table 2.9). No other variable 
was significantly associated with animal level CFT seroprevalence. 
 
Table 2.9: Animal-level multivariable model of risk factors predicting prevalence of contagious 
bovine pleuropneumonia based on cELISA and CFT results (seropositive herds only) 
 
 cELISA CFT 
Variable OR (95% CI) OR (95% CI) 
Age 
   2 
   3 








CBPP outbreak risk (Yes) 1.4 (1.1-1.8)*** 1.7 (1.2-2.5)* 
CBPP vaccination risk (Yes) 1.3 (1.0-1.7)** 1.0 (1.0-1.0) 
Trypanosomosis (Yes) 
1 
1.3 (0.9-1.7)  
Division (Mara) 
1 
1.4 (0.9-2.0)  
 
1.
 When variable trypanosomosis was dropped out of the model, division (Mara) became 
significant (p<0.05) and when division was dropped from the model then trypanosomosis 
became significant (p<0.05).  
2.




Multivariable model based on CFT results using all animals selected 
The multivariable model based on all animals indicated that animal being old enough to 
have been present during last CBPP outbreak was significantly (P < 0.05) associated 
with seroprevalence. Originating from a herd mixing at salt licks with five or more herds 
was protective whilst mixing with five or more herds at watering points increased the 
risk of being seropositive (Table 2.10) 
 
Table 2.10: Animal-level multivariable model of risk factors predicting prevalence of contagious 
bovine pleuropneumonia based on cELISA and CFT results (all herds included) 
 






   2 
   3 







CBPP outbreak risk (Yes) 1.4 (1.1-1.9)** 2.0 (1.3-3.1) 
CBPP vaccination risk (Yes) 1.4 (1.1-1.8)** 1.4 (0.9-2.1) 
Trypanosomosis (Yes) 1.3 (1.0-1.8)*  
Division (Mara) 2.0 (1.3-3.0)***  
Mixing at saltlick  0.7 (0.4-1.1)* 
Mixing at water  1.8 (1.1-2.9)** 
 





Based on animals from seropositive herds the proportion of cELISA seroprevalence that 
was attributable to exposure to previous vaccination and outbreaks were estimated at 
30% and 24%, respectively, while for CFT seroprevalence estimates of attributable 
fraction were 0% and 41%, respectively. Based on all animals, the proportion of cELISA 
seroprevalence that was attributable to previous exposure was estimated at 29% for both 
vaccination and outbreaks, while those for CFT seroprevalence were 50% and 29% for 
vaccination and outbreaks, respectively. Values reported for AF are based on OR-values 
and do not take into account whether or not the risk factors were significantly associated 
with seropositive results in multivariable analysis.  
2.3.7 Model diagnostics 
Changes in the herd-level estimates were observed when the model was re-run with one 
herd omitted at a time. A small number of herds (n = 4) from the Mara division caused 
considerable changes in the animal-model estimates based on cELISA results after they 




Figure 2.5: Model diagnostics indicating influential herds1  
 
 
CFT model: CBPP outbreak risk (Yes) 
 
CFT model: CBPP vaccination risk (Yes) 
 
cELISA model: CBPP outbreak risk (Yes) 
 
cELISA model: CBPP vaccination risk 
 
cELISA model: Age category 1.1 to 2 years 
 






Figure 2.5: Model diagnostics indicating influential herds1 (continuation) 
 
cELISA model: Age category >3 
 
cELISA model: Division (Mara) 
 




 Each symbol shows the results of the model after one herd is deleted from the dataset. The 
estimate is based on the final animal-level model (Logit (p)=β0 + Vaccination + Outbreak + 
Age(category 2-4) + Trypanosomosis + Division + bj + ε and Logit (p)=β0 + Vaccination + 
Outbreak + bj + ε based on cELISA and CFT respectively.; where  bj = herd effect ; ε=error 









2.4 Discussion  
Only three cross-sectional studies have been reported to estimate CBPP seroprevalence 
and risk factors in pastoral systems  (Bonnet et al., 2005; McDermott et al., 1987; Zessin 
et al., 1985), each of which focused on Ethiopia and Southern Sudan. The current cross 
sectional study aimed to provide an estimate of CBPP seroprevalence and associated risk 
factors in pastoral Maasai ecosystems of south-western Kenya. 
2.4.1 Seroprevalence estimates 
Reports on herd level CBPP seroprevalence based on the cELISA are limited. A cross- 
sectional study in the Ethiopian Highlands using cELISA found herd seroprevalence of 
4.6% (Bonnet et al., 2005), much lower than 85% observed in the current study. 
However, our observed CFT seroprevalence lies within the range reported for the 
pastoral system of southern Sudan under circumstances where vaccination had been 
practiced in the four years prior to the study  (Zessin et al., 1985). At herd level, an 
association was evident between seroprevalence and previous CBPP vaccinations. The 
study area was classified as “recently infected” in 1998 and, in 2003, reclassified as 
“infected” and hence vaccination and animal movement control was being practised  
(Wanyoike, 1999; Wanyoike-Kairu et al., 2004).  
 
Based on herds with at least one positive animal, animal level seroprevalences of 11.2% 
and 4.2% were estimated for cELISA and CFT, respectively. Animal seroprevalence of 
9.7% and 1.9% based on cELISA and CFT, respectively, were estimated based on 
animals from all herds. The estimated CFT seroprevalence were lower than the 10.5% 
seroprevalence reported for 13,251 samples submitted to the Central Veterinary 
Laboratory in Kenya between 1988 and 1998 (Wanyoike, 1999). Further, CFT 
seroprevalences of 8.1% (sample size = 1037) and 8.3% (sample size = 7036) were 
reported in two separate studies carried out in southern Sudan  (Zessin et al., 1985; 
McDermott et al., 1987). An abattoir serosurvey conducted in CBPP endemic areas in 
Nigeria estimated much higher seroprevalences of 32% and 27% based on cELISA and 
CFT, respectively  (Aliyu et al., 2003). The high animal CFT seroprevalences reported 
in these studies could be attributed to the non-random nature of sample selection in these 
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studies. For example, the higher seroprevalences observed in Kenya may be due to the 
fact that the samples were taken from animals suspected of CBPP  (Wanyoike, 1999), 
and the high estimates in Nigeria could be influenced by sick animals being sent for 
slaughter. The CFT animal seroprevalence estimate in the current study compares well 
with animal infection prevalence predicted for a pastoral system by a CBPP transmission 
model (Mariner et al., 2006). Furthermore, a seroprevalence of 4.9% was recently 
estimated in Kajiado, Kenya using CFT  (Matua-Alumira et al., 2006). The current study 
may have underestimated animal-level seroprevalence in the population because the age 
distribution of animals included in the seroprevalence study was not representative of 
the population as a whole. Based on the vaccine study (Chapters 4 and 5) it was 
observed that the population consisted of 22% young animals (≤3 years) and 78% adult 
animals (>3 years). However, in the seroprevalence study 56% of the sampled animals 
were young indicating that they were overrepresented compared to the population as a 
whole. Since the young animals had a lower risk of being seropositive than adult animals 
this may have resulted in underestimation of the seroprevalence.  
 
Agreement between CFT and cELISA was poor indicating that the two tests might be 
detecting different isotypes (Amanfu et al., 2000). CFT is said to be detecting IgM and 
possibly IgG1, which are able to fix complement, and cELISA is detecting IgG2 and 
possibly IgG1. Poor test agreement implies that serial interpretation of test results would 
lead to very low seroprevalence estimates. Therefore, separate models were developed 
for CFT and cELISA results in this study.  
2.4.2 Risk factor estimation 
Higher seroprevalence was associated with herds reporting previous CBPP vaccination. 
Vaccinated animals are expected to mount an immune response which could be detected 
by CFT or cELISA  (Masiga and Mugera, 1973; Geiger, 2003; Thiaucourt et al., 2000). 
Antibodies detectable by CFT have been reported as early as 5 days post vaccination and 




At the herd level, reported CBPP outbreaks were not significantly associated with 
seroprevalence. Reports of the persistence of antibodies following naturally occurring 
CBPP outbreaks were not observed during writing of the thesis. Nonetheless, in 
challenge trials, CFT positive test results have been reported from 7 days post infection 
(Barber et al., 1970) up to 5 months post infection  (Pearson and Lloyd, 1972). 
Persistence of antibodies for up to 19 months post challenge has been reported based on 
indirect ELISA  (Onoviran and Taylor-Robinson, 1979). The lack of an association of 
seroprevalence with previous outbreaks may arise from a masking effect of vaccination, 
since all herds that reported outbreaks also vaccinated. Another possible reason could be 
under-reporting of CBPP by the herders. This could be the case when animals 
experience subclinical disease, which is not noticed and reported by herders. Herders are 
capable of recognizing clinical signs but subclinical disease is defined by the absence of 
overt signs and may pass unnoticed  (Zessin et al., 1985; AU/IBAR, 2002). 
The current study established that seroprevalence was significantly higher in Mara than 
in Loita. This may be attributable to differences between the two divisions in contact 
structure. Contact structure, herd size and seasonal herding practices have been reported 
to influence CBPP disease distribution patterns  (Mariner et al., 2006 ;Zessin et al., 
1985). In this study, risk factors describing aspects of contact structure (mixing at 
watering points and salt licks, animals brought into herds) were considered and Mara 
division was characterized by a greater number of herds mixing at salt lick and watering 
areas, a greater tendency to bring back animals that fail to sell at market and a larger 
number of animals brought in through purchases and gifts. In univariable analysis based 
on cELISA, expected high risk strata for these factors were indeed associated with 
increased seroprevalence, but in the multivariable analysis, which included division, 
they were not significant. Conversely, contact structure-associated risk factors were not 
significant in univariable analysis based on CFT, but some were significant in 
multivariable analysis.  
 
Age was positively associated with seroprevalence as detected by both cELISA and 
CFT, which may be explained by the fact that increasing age is a surrogate measure of 
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repeated exposure (Boelaert et al., 2005). Similar findings were reported based on CFT 
analysis of samples from Sudan  (Zessin et al., 1985; McDermott et al., 1987). However, 
the age variable was still highly significant in the multivariable model, where exposure 
as a result of vaccination and outbreaks were accounted for. In addition to exposure to 
vaccination and clinical outbreaks, age could be indicating cumulative exposures to 
subclinical disease or infection with other Mycoplasma species that might cross-react 
with MmmSC  (Regalla, 1995). In the current study, female gender was significant in the 
univariable analysis, but not when other variables were accounted for in the 
multivariable model, as it was highly correlated with age. Similar findings were reported 
in other studies  (Zessin et al., 1985; McDermott et al., 1987). 
 
It was also observed that seroprevalence was positively associated with reported 
occurrence of trypanosomosis. This was unexpected because trypanosomal infection has 
been reported to have an immunosuppressive effect in cattle immunized against CBPP  
(Ilemobade et al., 1982). Trypanosomosis may be a proxy of division (Mara) or vice 
versa since the two were significantly correlated.  
 
The slight difference observed in the models based on seropositive herds and all herds 
could be attributed to the difference in structure of the two “populations”. The model 
based on cELISA seropositive herds only included a greater number of herds from Mara 
than Loita and thus created increased correlation between Mara and some variables that 
were highly reported in Mara (e.g. trypanosomosis). When all herds were included in the 
model, trypanosomosis and Mara division were independently associated with 
seroprevalence.  
 
The fact that CBPP is an infectious disease means that a true positive herd is likely to 
have more than one seropositive animal unless it is at the onset of the outbreak or a 
seropositive animal has just been brought into a clean herd. Figure 2.3 shows a bimodal 
distribution, with a mode at 0% within-herd seroprevalence and a second mode at 5% 
within herd seroprevalence. It is possible that herds with 2% seropositive animals (i.e. a 
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single animal) primarily represent false positive test results, whereas the second mode 
primarily represents a group of true positive herds, most of which would have multiple 
infected animals. The second mode appears to be surrounded by a normal to right-
skewed distribution starting at within-herd seroprevalence of 3%. When this value, i.e. ≥ 
3% of animals within a herd tested positive, was used as cut-off to define seropositive 
herds the same risk factors were significant in the herd-level model, and their 
significance level improved (results not shown). 
2.5 Conclusion and recommendations 
The study has estimated herd-level CBPP seroprevalences of 85% and 45.7% based on 
cELISA and CFT, respectively, in the study herds in the Maasai ecosystem of Kenya. 
Animal seroprevalences of 11.2% and 4.2% were estimated based on cELISA and CFT 
respectively, which may be an underestimate because young animals were 
overrepresented in the sample.  
 
The study shows that seroprevalence is significantly higher in herds reporting 
vaccination. This finding suggests that accurate CBPP diagnosis using serological assays 
is complicated in areas where vaccination is being practised. In addition, poor agreement 
between serological assays was observed. There is therefore a need for better diagnostic 
tests, specifically tests that can differentiate vaccination from infection/disease. 
 
The fact that some important risk factors, such as previous occurrence of CBPP 
outbreaks were not significantly associated with seroprevalence may indicate 
inadequacy of data based on herders recall, correlation between CBPP outbreaks and 
vaccination resulting in masking of the effect of outbreaks, or false-positive results at 
herd level due to the fact that herd-level specificity was compromised by multiple testing 
for the sake of herd-level sensitivity. To reduce probability of false positive herds, the 
cut-off value for the number of positive animals required for a herd to be declared 
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Chapter 3 - Spatial distribution of Contagious Bovine 




A spatial analysis was conducted to investigate the difference observed in herd 
seroprevalence of contagious bovine pleuropneumonia (CBPP) between Mara and Loita 
divisions of south-western Kenya. Herds were categorized as CBPP seropositive using 
two criteria, i.e. presence of at least one seropositive animal in the herd based on 
cELISA, or positive cELISA results for at least 3% of animals tested. Irrespective of cut-
off selected, a spatial scan statistic revealed CBPP clusters situated in the Mara division, 
a finding consistent with the increased seroprevalence based on the seroprevalence study 
(Chapter 2). The clusters identified based on the two diagnostic criteria at herd level 
showed partial overlap. Herds that were included in both clusters were found in areas 
identified as CBPP ‘hot spots’ by veterinary personnel.  
 Results from a logistic regression model showed that variation of seroprevalence 
in the two divisions was partly explained by agro-ecological zone and proximity to river 
with higher seroprevalence among herds located in the midland zone and near the river 
(water source). Additionally, the scan statistic proved to be a useful method for 
identifying CBPP ‘hot spots’. The high correlation between vaccination and Mara makes 
it difficult to determine whether the hot spot reflects a centre of infection or vaccination. 
The results further emphasize the need for developing a DIVA vaccine and 






Spatial concepts were first developed by a Russian parasitologist, Pavlovsky in the 
1930’s describing what he called ‘landscape epidemiology’. He stated, “Geographical 
variation in disease occurrence could be attributed to variations in the underlying 
biological or physical conditions which are required to support the pathogens, vectors 
and hosts and their probability of close encounter. If these biotic and abiotic factors were 
known and could be delineated, it could be possible to predict current and future 
distribution of a disease”  (Pavlovsky, 1966).  
 
“Disease maps provide a visual summary of complex geographic information and 
identify subtle patterns in the data that are missed in tabular presentations” (Elliot and 
Wartenberg, 2004). For example, mapping of CBPP outbreaks and cattle movement 
suggested an association between cattle movements and the maintenance and spread of 
the disease (Masiga et al., 1996). Mapping of CBPP outbreaks between 1988 and 1989 
in Kenya made it possible to report spread of disease into districts previously unaffected 
based on visual comparison of maps for different years  (Wanyoike, 1999). 
Advancement of technology for remote sensing and geographical information systems 
(GIS) has enabled identification of areas with increased risk, formulation of hypotheses 
about disease aetiology and assessment of needs for health resources  (Pfeiffer et al., 
2008). The production of attractive and informative disease maps complements spatial 
statistical analysis and results in larger visual impact on recipients than the 
accompanying statistics  (Rezaeian et al., 2004). 
 
 A number of clustering and cluster detection methods provide enhanced detection of 
areas of increased risk  (Besag and Newell, 1991; Kulldorff and Nagarwalla, 1995; 
Openshaw et al., 1987; Turnbull et al., 1990). These methods can broadly be classified 
as “global” when clustering is assessed across the study region without identifying a 
specific cluster location, and as “local” when the method identifies the location and size 
of the cluster. The Spatial scan statistic (SaTScan), developed by Kulldorf and 
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Nagarwalla (1997) has gained much use in the field of spatial epidemiology. Using this 
tool, Fèvre and colleagues (2001) reported expansion of rhodesiense sleeping sickness 
into previously unaffected districts within Uganda. The outbreak was initially centred 
close to a cattle market and spread outwards from the initial focus. The study further 
described risk factors associated with the spatial distribution of the disease. In a study to 
investigate spatial and temporal dynamics of acute respiratory disease in cattle in 
Hedmark and Oppland counties in the south eastern part of Norway, the spatial scan 
statistic indicated that outbreaks were clustered in space and time. Primary and 
secondary clusters were identified in areas with higher than expected disease incidence. 
Some of the affected herds were not included in any of the cluster groupings; and the 
authors suggested that a different transmission mechanism or even a different agent 
might be involved. In one affected district, detection of a disease cluster was attributed 
to reporting bias of farmers and veterinarians  (Norström et al., 2000). 
 
During a cross-sectional study of CBPP in the Maasai ecosystem of south-western 
Kenya, Mara was identified as having higher seroprevalence based on cELISA than 
Loita (P < 0.01) (Chapter 2). Spatial analysis was used to further investigate the 
observed difference between the two divisions. The expectation was that agro-ecological 
zones (AEZ) would influence farming systems in different areas; farming systems in 
turn will have effect on the herd size, seasonal herding practices and contact structure, 
which have been reported to influence CBPP distribution patterns  (Mariner et al., 2006; 
Zessin et al., 1985). During the cross-sectional study, animal movement, contact 
structure and herd size were accounted for in statistical models and were significant in 
the univariable model but no evidence of their influence on seropositivity was observed 
in the multivariable model. In addition, proximity to markets was expected to be 
associated with increased seroprevalenve because markets have been reported to be a 
source of infection for some diseases (Fèvre et al., 2001). Finally, proximity to river was 
expected to be associated with increased seroprevalence because of the possibility of 
increased contact between animals of different herds. It was hoped that additional 
investigation into spatial disease patterns would assist in elucidating the risk factors 
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underlying seroprevalence in Mara and Loita divisions. Insight into risk factors 
underlying disease distributions can lead to the development of recommendations for 
minimizing the impact of these risk factors, hence reducing the prevalence of the disease  
(Graham et al., 2005).  
 
 The objective of this study was therefore to describe spatial patterns of herd 
seropositivity observed in the Maasai ecosystem of south-western Kenya. Specifically, 
the study was aimed at: 
i. Identifying clusters of seropositivity  




3.2 Materials and methods 
3.2.1 Description of study area and design 
The current study made use of the data collected during a cross-sectional study carried 
out in Loita and Mara between July and September 2006. Details of the study design, 
sampling and laboratory analysis are given under “CBPP seropositivity and associated 
risk factor study in the Maasai ecosystem of south-western Kenya” (Chapter 2). Briefly, 
the number of herds to be sampled in each division was proportional to the total number 
of animals in each division. Within each division, administrative sub-locations were 
purposely selected to attain a wide geographical representation. Participants were then 
selected randomly from a sampling frame consisting of herders listed within selected 
sub-locations. Structured pre-tested questionnaires were administered to the selected 
farmers and simultaneously their herds were bled for estimation of herd seropositivity. 
All serum samples were analysed by competitive Enzyme Linked Immunosorbent Assay 
(cELISA) as described in detail in Chapter 2. Categorization of herds as seropositive 
was based on having at least one positive animal, or on a within herd seropositivity 
higher than 3% among animals tested. The number of animals tested ranged from 3-47 
per herd.  
3.2.2 Development of maps 
Global positioning system (GPS) coordinates were taken for each boma that was visited 
for interview and animal bleeding. Each boma was assigned a unique number, which 
was used consistently in the analysis. In addition, GPS records were taken for market 
centres nearest to the visited boma. The coordinates taken were in latitude/longitude 
format and were recorded using a hand held Garmin eTrex Vista (Taiwan) receiver. The 
coordinates were then imported into ArcView GIS 3.2 (Environmental Systems 
Research Institute (ESRI), Inc., Redlands, USA) as database file (DBF3) and projected 
into Universal Transverse Mercator 1983 (UTM83), zone 36 S and converted into shape 




Maps for AEZs and rivers were downloaded from International Livestock Research 
Institute (ILRI) GIS databases (http://www.ilri.org/gis/search.asp). These maps were in 
geographic coordinate system: GCS_Arc_1960, datum: D_Arc_1960 and were also 
projected in to UTM83, zone 36 S. Agro-ecological zones were based on the Farm 
Management Handbook of Kenya (Jaetzold and Schmidt 1983), digitized by Kenya Soil 
Survey and Kenya Agricultural Research Institute (KARI). Coverage showed the AEZs 
of Kenya based on annual mean temperature belts, i.e. upper highland (10 to 15˚C), 
lower highland (15 to 18˚C), upper midland (18 to 21˚C), and lower midland (21 to 
24˚C). The original aim of the map was to provide the frame-work for ecological land-
use potential. The map for rivers was originally called “Klriversis” and coverage 
showing rivers of Kenya was provided by the Japan International Cooperation Agency. 
The map with herd locations was then overlaid onto the AEZ map. AEZ information was 
extracted and four zones were identified (upper and lower highland, upper and lower 
midland) which were categorized into a single highland zone (10-18˚C) and a single 
midland zone (18-24˚C) for use in the model. The map with market centres was also 
overlaid onto the map with herd locations, and the map with herd locations was further 
overlaid onto the map of Kenyan rivers. Distances to the nearest market centres and 
rivers were extracted using the spatial analyst extension called “nearest feature” 
(ArcView 3.2, ESRI, USA) and used in the models.  
3.2.3 Statistical analysis 
First, exploratory analysis of data was performed, based on spatial cluster analysis using 
SaTScan version 7.0.3 (http://www.satscan.org/references.html; last accessed 14th April 
2009). A detailed account of the theory behind the methodology is given elsewhere  
(Kulldorff et al., 1997; Kulldorff and Nagarwalla, 1995). Briefly, the SaTScan test 
detects the most likely clusters of events in a data set and infers their significance using 
Monte Carlo replications. In our analysis, cluster detection was purely spatial as the 
study was a cross-sectional study and did not include time variables. SaTScan imposed 
circular windows centered on each of the coordinates located in the study area. For each 
coordinate, the radius of the window ranged from the smallest inter-event distance to 
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typically the distance that contains 50% of the population in the study area. A likelihood 
ratio test for each potential cluster was then calculated by comparing the alternative 
hypothesis of increased risk of disease inside the circle and the null hypothesis of equal 
risk inside and outside the circle. Non overlapping clusters were identified. Separate 
cluster tests were performed for the two methods of identifying CBPP test-positive 
herds.  
 
The second part of the analysis was based on predictive regression models to identify 
risk factors associated with the spatial distribution of herd seropositivity. The dependent 
variable was whether the herd was classified as CBPP positive or CBPP negative. Two 
separate models were developed for the two methods of categorizing CBPP positive 
herds. Explanatory variables were limited to independent variables that were considered 
to influence the spatial pattern of the disease, i.e. AEZ, proximity to market centres and 
proximity to rivers. Independent variables that were significantly positive at all levels of 
variable in the univariable herd model based on cELISA results (Chapter 2) were re-
evaluated in the model, because the current analysis included only 166 of the 175 herds 
from the original analysis. The variables included were vaccination (yes/no), number of 
vaccinations (none, one, more than one in the past 10 years), and trypanosomosis 
(yes/no) listed by the herder among the five most important diseases affecting his herd). 
Since the chapter was based on identifying underlying parameters that could explain the 
difference between the two administrative units (Mara and Loita divisions), division was 
not included as independent variable. Univariable analysis was performed for all 
variables (variables influencing the spatial pattern of the disease and taken from Chapter 
2). All analyses were performed using the STATA statistical package (Intercooled 8th 
version; StataCorp: Texas, USA). The model was built by backward elimination with P 
value set at ≤ 0.10 for retention in the model. The general equation is given by 
 




where p = outcome (positive or negative for CBPP); β0 = intercept; βi = regression 
coefficient for risk factor i; Xi = value of risk factor i; ε = error term. Regression 
coefficients were the natural logarithm of the odds ratio  (Pfeiffer et al., 2008). Cross 
tabulation was carried out to assess correlation between independent variables based on 
the Chi statistic. Mean proximity to river for herders reporting/not reporting 
trypanosomosis among important diseases was analysed based on the t-test. Variables 
that were considered for inclusion in the analysis are described in Table 3.1. 
 
Table 3.1: Description of variables included in the models for CBPP detection in Maasai herds in 
the south-western Kenya 
 
Dependent variable Description 
AEZ Agro ecological zones (Highland; Midland) 
Proximity to river Distance from the river as continuous variable in km  
Proximity to market  Distance from market as continuous variable in km 
CBPP vaccination CBPP vaccination carried out in the past 10 yrs (Yes/No) 
CBPP vaccination number Number of years in which CBPP vaccination was carried out 
over past 10 years (1=not vaccinated; 2=once; 3=twice and 
more) 
Trypanosomosis Trypanosomosis listed among 5 important diseases by 




3.3 Results  
3.3.1 Herd characteristics 
In total, 175 herders participated in the cross sectional study. For 9 herders, locations 
were lost upon overlay with the AEZ map of Kenya and full data was available for 166 
herders, i.e. 129 from Mara and 37 from Loita (Figure 3.1). 
 
















 Herd size ranged from 6 to 450 cattle with a median of 70. The majority of herders 
(71%) were located in the midland zone; herds in Mara were predominantly located in 
the midland zone whilst herds in Loita were more likely to be in the upland zone (P < 
0.01). Most herders (81%) reported vaccinating against CBPP in the past ten years 
(Table 3.2). 
 
Table 3.2: General characteristics of the study herds 
 
Variable Levels Loita  Mara 
Categorical   Herds (%) Herds (%) 





























Continuous  Median (range) Median (range) 
Proximity to river (km)  2.6 (0.05-8.4) 2.0 (0.01-8.04) 
Proximity to market (km)  4.0 (0.74-9.1) 7.8 (0.28-21.2) 
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3.3.2 Seropositivity and cluster detection 
A total of 141 out of 166 herds had at least one positive animal resulting in 85% of herds 
being classified as CBPP positive based on this criterion. Based on this categorization of 
test-positive herds, one significant cluster was detected with 47 positive herds. This was 
significantly higher than the expected number of positive herds (n = 40), giving a 
relative risk of 1.3 (P < 0.05). The cluster was located in Mara division (Figure 3.2 and  
Table 3.3). A non significant secondary cluster was also identified (results not shown). 
 
Figure 3.2: Cluster of CBPP positive herds identified based on SaTScan using model with herd 












Seventy three percent (73%) of herds were classified as CBPP positive based on 
categorization of herds as positive if within herd seropositivity was greater than 3%. The 
SaTScan test detected one most likely cluster with 60 seropositive herds, a significantly 
higher number of seropositive herds than expected (47 herds), giving a relative risk of 
1.53 (P < 0.05) (Table 3.3).  
 
Table 3.3: Details of spatial clusters of CBPP positive herds in Mara and Loita divisions of 




Variable CBPP definition 1 CBPP definition 2 
Most likely cluster location 
   Latitude 








P – value 0.005 0.001 
Observed/expected number of cases 1.18 1.27 
Relative risk 1.27 1.53 
Log likelihood 9.17 11.56 
Radius (km) 34.65  42.14 
 
1. CBPP definition 1: Herd CBPP positive if ≥ 1 animals cELISA positive; CBPP definition 2: 











The cluster covered most of Mara division (Figure 3.3). A non significant secondary 
cluster was also identified (results not shown). 
 
Figure 3.3: Cluster of CBPP positive herds identified based on SaTScan using model with herd 






3.3.3 Proximity to market centres and rivers 
Proximity to market centre ranged from 0.3 km to 21.2 km with median at 6.8 km. Boma 
tended to be located close to rivers and proximity to rivers ranged from 0.01 km to 8.4 
km with median of 2.1 km. The boma locations were connected to the nearest market 
centre and river (Figure 4 and 5) regardless of the actual use of the market centre or 
river. Two market centres within the study area were far from any of the selected herds 
and did not have connecting lines. For some herds, the nearest market centre was outside 
the divisions that were part of the study.  
 
Figure 3.4: Location of herds (green dots) and market centres (purple dots) showing shortest 





























3.3.4 Statistical analysis 
Based on univariable analysis, herds were more likely to be CBPP-positive if they were 
located in the midland zone, close to a river, or far from a market, and if they had 
vaccinated against CBPP in the past or listed trypanosomosis among the five most 
important diseases affecting their herds. These results were obtained based on both 
methods of classifying herds as CBPP-positive, with minor differences in estimates for 








  CBPP definition 1 CBPP definition 2 
Variable Herds Seropositivity 




 (95% CI) 
Odds ratio
2 
Herd level  84.9 (79.4-90.4)  72.9 (66.1-79.7)  
AEZ 
   Highland 

















   Yes 
















CBPP vaccinations number 
   0 
   1 






















   Yes 
















Proximity to river 166  0.83 (0.69-1.00)*  0.85 (0.72-0.99)** 
Proximity to market centres 166  1.14 (1.01-1.29)**  1.08 (1.00-1.17)* 
 
1.
 CBPP definition 1: Herd CBPP positive if ≥ 1 animals cELISA positive; CBPP definition 2: Herd CBPP positive if >3% of animals that 
were tested were cELISA positive. 
2. P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
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Based on multivariable analysis, midland zone, vaccination and proximity to rivers were 
associated with increased risk of being CBPP positive based on detection of at least one 
seropositive animal in a herd, whilst vaccination, proximity to rivers and trypanosomosis 
were associated with increased risk of being CBPP positive based on at least 3% 
seropositive animals (Table 3.5).  
 
Table 3.5: Multivariable model identifying risk factors for CBPP positive herds in Mara and Loita 
divisions of south-western Kenya based on cELISA
1 
 
Variable  CBPP definition 1
 




Odds ratio (95% CI)
2 
AEZ (Midland) 3.40 (1.20-9.62)** 2.78(1.22-6.32)** 
Vaccination (Yes) 3.32 (1.19-9.22)** 2.36 (0.96-5.78)* 
Proximity to river 0.80 (0.64-1.01)* 0.82 (0.69-0.99)** 
Trypanosomosis (Yes)
 3
 3.03(1.08-8.53)** 3.56 (1.59-8.00)*** 
 
1.
 CBPP definition 1: Herd CBPP positive if ≥ 1 animals cELISA positive; CBPP definition 2: 
Herd CBPP positive if >3% of animals that were tested were cELISA positive. 
2.
 P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01 
3.
 AEZ is significantly correlated with trypanosomosis. When the variable AEZ is omitted from 
the model then trypanosomosis, become significant (P < 0.05 and P < 0.01 for definition 1 
and 2 respectively) 
 
 
Four variables were highly correlated, i.e. Midland was positively correlated to Mara 
division, CBPP vaccination and reporting trypanosomosis among important diseases 
(Table 3.6). Based on the t-test, mean proximity to river among herders reporting 
trypanosomosis as important disease was not different from herders not reporting it as 













Table 3.6: Cross tabulation of independent variables associated with the risk of CBPP in the 












Vaccination (Yes)  19.44 16.03 23.32 
AEZ (Midland) 0.00  56.90 56.67 
Trypanosomosis 
(Yes) 
0.00 0.00  21.92 
Division (Mara) 0.00 0.00 0.00  
1.




This is the first report on CBPP spatial clusters and associated risk factors identified 
based on cELISA. A significant cluster of CBPP positive herds was identified with each 
of two separate Bernoulli models using different cut-offs to classify herds as CBPP 
positive. Both clusters were located in Mara. The cluster based on herds classified as 
positive if at least one animal was positive tended to be smaller than the cluster based on 
classification of herds as CBPP positive if more than 3% of the animals that were tested 
within the herd were seropositive. Despite the difference in size and location, 42 herds 
were included in both clusters. These herds fall within areas such as Sekenani, Talek, 
Olesere and Aitong, which are among areas marked as CBPP “hot spots” in the district 
(Mark Lemein (2009), personal communication). Such areas might act as a centre of 
endemicity and may be a source of infection to other parts of the country through animal 
movements and tribal exchanges. However, the high correlation between vaccination 
and Mara where the clusters are based makes it difficult to determine whether the ‘hot 
spots’ reflect centres of infection or vaccination. The results further emphasize the need 
for developing DIVA vaccines and corresponding diagnostic tests to make 
differentiation of infected and vaccinated animals possible.  
 
Based on the regression model, midland zone and CBPP vaccination were positively 
associated with classification of a herd as CBPP positive. Based on a Chi-square 
statistic, Mara and Loita were significantly different with regards to AEZ, with herds in 
Mara predominantly located in the midland zone and herds in Loita in the highland zone. 
Agro-ecological zones were hypothesized to predict farming systems practiced in the 
area, which in turn could have impact on the CBPP distribution. AEZ could play a 
potential role in maintaining CBPP in the study area through its influence on farming 
system (herd sizes, animal movements and contact structures). Indeed, herd sizes, animal 
movements and contact structures were significant in the univariable model based on the 
cross-sectional studies. They were highly correlated with division and other independent 
variables and dropped out of the multivariable model (Chapter 2).  
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In univariate and multivariate models, herds located near the river edge had increased 
risk of being classified as CBPP positive compared to herds located far from the river 
edge, regardless of classification criteria. Proximity to water sources has been reported 
to be associated with increased risk of trypanosomosis (Michel et al., 2002). 
Trypanosomosis was reported among important diseases prevalent in the area. The 
disease causes immunosuppression, which may make animals more susceptible to 
disease or unable to mount a good immune response upon vaccination  (Ilemobade et al., 
1982). Mean proximity to river was not different for herders reporting and not reporting 
trypanosomosis among important diseases, so the effect of proximity to river cannot be 
attributed to trypanosomosis. Fifty percent of herders resided within 2 km from the river 
edge. This suggests that animals located near the river edge may be in close contact, 
which could increase the probability of disease spread among them. Proximity to 
livestock market centres was expected to be a risk factor for seroprevalence as observed 
for rhodesiense sleeping sickness reported in Uganda (Fèvre et al., 2001). This was not 
observed in the current study, possibly because not all nearest market centres engaged in 
livestock trade and even if they did, they were not necessarily the herders’ preferred 
markets. Another explanation could be that herders staying far from the market are at 
increasing risk because animals purchased from the market had to be trekked over a long 
distance, increasing their possibility of contracting disease and introducing into the herd.  
3.5 Challenges/limitations 
The current study used the data obtained during a cross-sectional study. Participating 
herders were randomly selected and the selection was fit for that purpose. However, this 
type of selection may not be fit for all types of studies. For spatial analysis, spatial 
systematic sampling or stratified random sampling based on knowledge of spatial 
structure would have been more appropriate  (Longley et al., 2005). For example, AEZs 





Locations of herders were condensed into single points. The benefit of using single 
points includes ease of data storage and manipulation and simple visual output  
(Carpenter, 2001). For farmed animals, herd locations are not points but areas, 
represented by polygons. For the Maasai pastoral system, a farm area would not provide 
additional information since animals are not confined to farms. In our study, coordinates 
were taken at an arbitrary point close to the boma. The use of a standardized method to 
choose the point for which GIS data were collected would have been preferable  
(Pfeiffer et al., 2008; Durr and Froggatt, 2002).  
 
Spatial data are often obtained from various sources; for instance, the data used in the 
current study were obtained from field recordings (with precision of ≤ 8 m) and the 
ILRI-GIS database (http://www.ilri.org/gis/search.asp; accessed on 18th February 2009). 
The data were in different geographical projections and had to be converted to UTM83 
zone 36 S. According to Monmonier (1996), map projections distort geographical 
relationships and therefore may results into errors. 
3.6 Conclusion  
The current study identified clusters of CBPP-positive herds, which had been identified 
using cELISA test results. Based on the spatial scan statistic, two clusters located in 
Mara were identified. Some herds were included in both clusters and were located in 
areas identified as CBPP ‘hot spots’. The high correlation between vaccination and Mara 
makes it difficult to determine whether the identified ‘hot spots’ reflects a centre of 
infection or vaccination. Results from a logistic regression model showed that 
seropositivity in the two divisions was partly explained by agro-ecological zone 
difference and proximity to river. Higher seropositivity was associated with herds 
located in the midland zone and near the river (water source). Additionally, vaccination 
and reporting trypanosomosis were highly associated with seropositivity. The results 
further emphasize the need for developing DIVA vaccine and corresponding diagnostic 
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Chapter 4 - A comparative CBPP vaccine safety study in the 
Maasai ecosystem of south-western Kenya 
Abstract 
A double-blind CBPP vaccine trial was carried out including 79,959 cattle in 458 herds 
in the Loita, Mara and Osupuko divisions of Narok District, Kenya, between February 
and July 2007. A standard vaccine (Contavax®) currently used in Kenya for control of 
CBPP and a buffered vaccine formulated as suggested by March (2004) were compared. 
The aim of this study was to identify and quantify adverse events post-vaccination and 
to compare incidences of adverse events between vaccine types. Adverse events 
observed within 100 days post-vaccination were classified into specific (swollen tail, tail 
slough, wounds or swelling in the perineal or gluteal region), non-specific (weakness, 
lameness, abortion and mortality) adverse events and antimicrobial treatments.  
  486 adverse events were reported among all vaccinates of which 326 (4.1 per 
1000) were specific and 160 (2.1 per 1000) were non-specific. A subset of animals was 
subjected to detailed follow-up (n = 2038 animals in 58 herds); the incidence of adverse 
events in the subset was 2 to 3 times higher than in the complete study population. The 
highest recorded incidence was for ‘swollen tail’, whilst ‘wounds in the perineal region’ 
were rare in both populations. The incidence of antimicrobial treatments per 1000 
animals was 12.7% in all vaccinates and 16.2% in the subset.  
  The effect of vaccine on the odds of a reported adverse event (specific, non-
specific, or antimicrobial treatment) was analysed using generalized linear mixed 
models. The study shows that the buffered vaccine was associated with increased odds 
of specific adverse events when compared to the standard vaccine. The effect of the 
vaccines on specific adverse events was modified by age, gender and division. Adult and 
female animals vaccinated with the buffered vaccine had higher odds of specific adverse 
events compared to those vaccinated with the standard vaccine, whilst no difference 
between vaccines was observed in young and male animals. In all three divisions, 
animals vaccinated with the buffered vaccine had an increased odds of specific adverse 
events compared to those vaccinated with the standard vaccine, and animals from 
Osupuko had increased odds of specific adverse events compared to animals from both 
other divisions. No effect of vaccine type was observed on the odds of non-specific 
adverse events. However modification effect of division was observed. Vaccination with 
buffered vaccine was associated with increased odds of antimicrobial use and this effect 
was not modified by age, gender or division.  
 The current study shows that the odds of specific adverse events was higher for 
animals vaccinated with the buffered vaccine compared to animals that were vaccinated 
with the standard vaccine. Modification of the vaccine effect by age, gender and origin 
suggests that naïve populations (young cattle and cattle in Osupuko, where farmers were 
less likely to have reported outbreaks and/or vaccinations within the past 10 years) were 
at higher odds of adverse events than populations with prior exposure to CBPP or CBPP 
vaccine. Vaccine safety should be given due consideration when developing more 




Contagious bovine pleuropneumonia (CBPP) post-vaccination adverse events were first 
documented in 1849 when Louis Willems demonstrated that inoculation of serous fluid 
from CBPP infected lungs into healthy cattle caused pronounced local reactions. This 
crude method resulted in a high percentage of severe post vaccine reactions (10%) and 
deaths (1%) which prompted a search for safer vaccines  (Huygelen, 1997). Broth 
vaccines based on T1 and KH3J strains of Mycoplasma mycoides subsp. mycoides 
(MmmSC) have been developed and used widely for CBPP control in endemic African 
countries in the 1960s and early 1970s. These vaccines were fragile and freeze-dried 
formulations with improved viability were later developed and used for the control of 
disease. In the 1980s a streptomycin resistant strain of T1 and KH3J (T1/sr and KH3J/sr 
respectively) were also developed for use in the combined Rinderpest-CBPP vaccination 
campaigns (Lubroth et al., 2007).  
The vaccines are administered subcutaneously at the tail-tip or behind the shoulder 
(Masiga and Windsor 1974; Gilbert et al., 1970; Lindley, 1967; Davies et al., 1968). The 
KH3J vaccine was reported to cause no adverse events but was less immunogenic and 
hence withdrawn (Mowat and Rweyemamu, 1997). Tail tip administration of T1/44 
vaccine was associated with adverse events  (Daleel, 1971; Revell, 1973). A general 
description of the adverse events post-vaccination was given by Provost et al., (1987) 
and adverse events were characterized by erythema and swelling extending over part of 
the tail. In some animals swelling extended to the whole tail and into the gluteal and 
perineal regions, ending in fatality. Vaccination behind the shoulder resulted in 
development of a transient local oedematous swelling resulting in necrosis in some 
animals.  
 
Detailed field studies on adverse events post CBPP vaccination are limited. An 
incidence of 0.8% was reported based on a retrospective study where 296,248 animals 
were vaccinated against CBPP using freeze dried T1/44 vaccine in Ethiopia  (Sori, 
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2005). The study also reported 0.17% mortality. The author suggests that contamination, 
intramuscular injection and poor body condition were among factors contributing to the 
incidence of adverse events post-vaccination. Revell (1973) reported tail-tip slough in 
12% of 6,673 animals vaccinated with freeze-dried T1/44 vaccine in an ‘infected’ area in 
Zambia. The same author reported tail-tip slough in 0.17% out of 1,162 vaccinated 
animals from an ‘uninfected’ area bordering the infected area. Two out of 86,035 
vaccinated animals experienced swelling at the vaccination site based on a T1 broth 
vaccine in Sudan  (Daleel, 1971). In addition to poor safety, the T1/44 CBPP vaccine has 
been reported to have poor efficacy (Thiaucourt et al., 2000; Karst, 1972). Low vaccine 
titres attained during production were reported as a major factor behind this poor 
efficacy  (Rweyemamu et al., 1995). 
 
Two vaccine types were used for the current study. One vaccine was manufactured 
based on the standard method used for production of the vaccine that is currently used 
for control of the disease in Kenya. The other vaccine was manufactured based on a 
buffering formulation suggested to maintain stable vaccine titre during production and 
use  (March, 2004; Waite and March, 2001). It was hypothesized that maintenance of a 
higher vaccine titre by buffered vaccine would be associated with higher 
immunogenicity and, possibly, more reactogenicity. Based on a limited vaccine trial 
carried out at Kenya Agriculture Research Institute (KARI) in Muguga, in advance of 
the work reported here, mild swelling at the site of inoculation was observed between 3 
and 20 days post-vaccination using standard or a buffered vaccine (Wesonga H. and 
Schnier C. 2008, personal communication). 
This study was undertaken to compare the safety of the standard freeze-dried T1/44 
CBPP vaccine with the buffered formulation under field conditions. The specific 
objectives of the study were to:  
 
i. Identify and quantify adverse events post-vaccination 




4.2 Materials and methods 
4.2.1 Description of the study area and selection of crushes 
A CBPP vaccine field trial was carried out between February and July 2007 in Narok 
South district in Kenya. The district borders Kajiado on the east, Transmara on the west, 
Narok North on the north and Loliondo district of Republic of Tanzania on the south. 
CBPP vaccination involved cattle from three divisions within Narok district; namely 
Osupuko, Mara and Loita. The divisions are inhabited by Maasai communities whose 
livelihood depends mostly on pastoral and agro-pastoral systems. Vaccination was 
carried out at 19 crushes selected from 38 listed in the three divisions. Selection of the 
crushes was without any formal randomization and was based on the working condition 
of the crushes. Also, for logistical reasons selected crushes had at least 2,000 
unvaccinated animals living within the villages or clusters served by the crush, a number 
that was supplied by the District Veterinary Office in collaboration with Naroosura 
Agro-Vet Services. Of the 19 crushes, 7 were in Mara, 6 were in Loita and 6 were in 
Osupuko. Allocation of crushes to two vaccinating teams was carried out in such a way 
that two neighbouring crushes were allocated to either of the two teams.  
4.2.2 Type, source, reconstitution fluid and storage of the CBPP vaccine  
Two CBPP vaccines, manufactured in January 2007 by Kenya Agriculture Research 
Institute - Veterinary Vaccine Production Centre (KARI-VVPC) based in Nairobi, were 
used. The vaccines were presented in 5 ml glass vials as a freeze-dried material with 
batch number 01/07. One vaccine was the standard (Contavax®) vaccine based on freeze 
dried live attenuated MmmSC T1/44 vaccine cultured in un-buffered growth media with 
10% glucose, and was reconstituted with normal saline. The standard vaccine is 
currently used in Kenya and other African countries for control of CBPP. The buffered 
vaccine was a freeze-dried live attenuated MmmSC T1/44 vaccine, cultured on N-2-
Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES)-buffered culture media  
(March 2004; Waite and March 2001). The buffering system prevents a drop in pH 
hence maintaining optimal titre during vaccine production. The same authors suggested 
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the use of phosphate-buffered saline (PBS) as a reconstitution fluid to offer additional 
buffering effect. Both vaccines had the same batch number and were packed in similar 
containers; it was therefore decided to label one with red marker and the same labelling 
was used for the respective reconstitution fluid. Reconstitution fluids (PBS and normal 
saline) were packed in 50 ml plastic bottles. Reconstituted vaccine vials had 
approximately 100 vaccine doses. Vaccines and accompanying reconstitution fluids 
were collected from the KARI-VVPC two days prior to start of vaccination. Vaccines 
were transported in dry ice to Narok where they were kept frozen at -20°C. During 
fieldwork, both vaccines were kept in a freezer compartment of a refrigerator located at 
a central point under supervision of the author. Sufficient vaccine doses for a particular 
crush were assigned to team leaders each time the teams moved to a new crush.  
4.2.3 Composition of the teams and pre testing of protocols 
Vaccines were administered by two teams, which were named Narok and Naroosura. 
Each team had a veterinarian, animal health assistants and a community animal health 
worker. The Narok team was composed of employees from District Veterinary Office, 
the office responsible for planning and regulating veterinary services in the district. The 
Naroosura team was composed of staff from Naroosura Agro-Vet Services; a privately 
owned veterinary centre that provides agro-vet inputs and animal health services in 
Osupuko and Loita divisions. Private veterinary facilities are regulated by state 
veterinarians based in the district veterinary office, which implies that they work in a 
similar manner. Prior to the vaccination exercise, two days of training (11th -13th January 
2007) were carried out to impart team members with common understanding of the 
vaccination and monitoring protocols. In addition, pre-testing of protocols was carried 
out in order to harmonize vaccination, bleeding and recording methods.  
 
Sensitization of the community leaders and society at large was carried out from 16th to 
30th January 2007 using a pre-designed message detailing how and by whom the vaccine 
would be administered, how the monitoring would be carried out and how farmers 
would benefit from participation (Appendix ii). 
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4.2.4 Vaccination protocols  
The trial was double-blind in that neither vaccinators nor personnel monitoring 
vaccinated animals were aware of the type of the vaccine that had been administered to 
the animal. Vaccination was carried out such that all animals in a full crush (20-30 
animals) were vaccinated with one type of vaccine. The crush was then emptied and 
filled with another lot, all of which received the other type of vaccine. Animals were 
injected with 0.5 ml of the reconstituted vaccine subcutaneously at the base of the tail 
switch using hypodermic needles (17G x ½”, Hauptner, Germany) and automatic 
syringes (10 ml; Hauptner, Germany). The route is generally referred to as “tail tip” but 
practically vaccine is not injected at the tip since injecting 0.5 ml at the tip of the tail will 
often require pressure to empty the syringe and may result in the needles being forced 
off the nozzle. Vaccination needles were replaced for every fresh reconstitution of 
vaccine, which were approximately 100 doses. Reconstituted vaccines were placed 
inside cool boxes packed with ice blocks; each type in a separate cool box. Two data 
loggers (Tinytag, UK) were programmed to record temperature every 10 minutes and 
each was placed inside the cool boxes on arbitrary days. Time from vaccine 
reconstitution to end of use (‘Vaccine use time’) was additionally recorded on the same 
days as the cool box temperatures were monitored. 
 
On average, 1000 animals were vaccinated per day by each team. At herd level, effort 
was made to have half of the animals vaccinated with each of the vaccine types. All 
vaccinated animals were ear tagged; animals vaccinated with red marked vaccine were 
right ear-tagged and animals vaccinated with unmarked vaccine were left ear-tagged. 
This method of ear tagging was designed to ease identification of animals during 
subsequent vaccinations. It was thought that this would not bias follow-up studies 
because personnel involved in vaccination and monitoring had no idea of vaccine type 
associated with either right or left ear tagging. Background information such as age, 




4.2.5 Study population and selection and use of subset 
It was planned to include approximately 100,000 animals from 500 herds in the study. 
This was based on the assumption that very few vaccinated herds (approximately 5%) 
would break down with clinical CBPP within one year of follow-up. Given the low 
expected incidence, large numbers of animals were included in order to find a small 
improvement in the vaccine’s ability to prevent clinical disease. 
 
Twelve out of 19 crushes were purposely selected, and from each crush, 5 herders were 
selected to participate in the detailed safety study, which involved tail measurement and 
bleeding pre- and post-vaccination. The results from bleedings are presented in the 
vaccine efficacy study (Chapter 5). Inclusion of herders was based on their willingness 
to comply with bleeding schedules and regular visits as per study protocol. Sample size 
calculations are detailed in the vaccine efficacy study (Chapter 5). Briefly, a sample size 
of 2400 animals was calculated to estimate 5% seroconversion difference between 
animals vaccinated by either vaccine. Animals were drawn from 60 herds, each 
contributing 40 conveniently selected animals (20 animals vaccinated with each vaccine 
type). The tail diameters of selected animals were measured using vernier callipers pre- 
and post-vaccination to assess the change in tail diameter and the measurements were 
taken at the base of the tail switch (inoculation site). Pre-vaccination tail measurements 
were carried out at the crush site (Appendix iv).  
4.2.6 Post-vaccination monitoring 
All vaccinated animals, regardless of inclusion in the subset, were actively monitored by 
trained community animal health workers visiting weekly for the first month post-
vaccination and thereafter monthly for the purpose of recording adverse events. Adverse 
events observed within 100 days post-vaccination were recorded in the specific 
monitoring forms (Appendix v). Tail measurements were carried out approximately one 
month and three months post-vaccination. The follow-up measurements were carried out 
at herders’ homesteads. Information on prior CBPP exposure through outbreak and 
vaccination was also collected during the follow-up visits (Appendix iv).  
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4.2.7 Statistical analysis  
Adverse events were classified into specific events (swollen tail, tail-tip slough, and 
wounds and/or swellings in the perineal or gluteal region), non-specific events 
(weakness, lameness, abortion and mortality) and antimicrobial treatments. Descriptive 
statistics, graphics and logistic regression modelling were carried out using statistical 
package STATA (Inter cooled 8th version; StataCorp, Texas, USA). Logistic regression 
models were developed for each outcome; specific, non-specific and antimicrobial 
treatments, and models were based on all vaccinates. The final models were based on 
generalized linear mixed models (GLMM) using GenStat (Release 10.2; Copyright 
2007, Lawes Agricultural Trust, Rothamsted Experimental Station) based on the general 
equation [1] 
 
 logit (p)=β0+ β1vaccine typeij+ β2Xij+ β3 (vaccine typeij* Xij)+(bj)k + ε;         [1] 
 
where, β0 = intercept; β1 = regression coefficient for vaccine type; β2 regression 
coefficient for independent variable; β3 = regression coefficient for interaction between 
vaccine type and independent variable; Xi = value for independent variable (age, gender, 
team, body condition score, and animal origin); bj = random effect for herd (j) in  crush 
(k); ε = error term. Vaccine type was the only independent variable that was kept in all 
models. ‘Crush’ and ‘herd’ were included as random effects. A detailed description of 




Table 4.1: Description of variables included in the models 
 





Adverse events that were reported within 100 days post-vaccination  
 
Specific adverse events: swollen tail or swollen tail base; tail-tip slough off; 
involvement of gluteal muscles and wounds at the vaccination site and/or near 
tail base; with or without non-specific adverse events (No; Yes). 
 
Non-specific adverse events: abortion; lameness; weakness; mortality (No; 
Yes) 
Antimicrobial treatments: Antimicrobial (tetracyclines 10% and 20% brands) 
use with or without recording of a specific or non-specific adverse event (No; 
Yes) 
Age  Age in years (Young: ≤3 yrs; Adult: >3 yrs) 
Herd Group of animals vaccinated under one herder name 
Body condition Body condition score (Good; Fair) 
Crush Vaccination site  
Loita: Enkoseremai, Entasekera, Morijo, Nkopon, Olmesutie and Olorte. 
Mara: Sekenani, Oldisare, Oloonchora, Ololturoto, Olpusimoru, Orkinyei and 
Talek. 
Osupuko: Elang’ata Enterit, Naroosura, Nkimpa, Ntuka, Olepariata and 
Oloigeruno. 
Division Administrative unit (Loita; Mara; Osupuko) 
Gender  Animal gender (Male; Female) 
Tail change Tail diameter post-vaccination less diameter pre-vaccination in cm. 
Temperature  Cool box temperature (°C) calculated from the data logger records 
Use time End time use minus time of reconstitution (minutes). 
Team  Vaccine delivery team for an individual animal (Narok team; Naroosura team) 




4.3.1 Description of the general study population 
In total 79,959 animals from 458 herds were vaccinated against CBPP. Of these, 49.1% 
were administered the standard vaccine and 50.9% the buffered vaccine; 52.6% of the 
animals were vaccinated by the Narok team and 47.4% by the Naroosura team. Most 
animals (99.4%) were zebu in good body condition (Table 4.2).  
 
A subset of 60 herders (20 herders from each division) participated in the detailed CBPP 
vaccine safety study. Two herds were lost at the first post-vaccination follow up because 
the herders refused to have their animals bled and examined according to study protocol. 
A total of 2414 animals were recruited, complete data was available for only 2038. 
Incomplete data was due to difficulty in identifying the animals during follow up visits 
because the cattle marker that was used had faded. The composition of animals and 
distribution of teams and vaccines in the subset were similar to the complete study 
population (Table 4.2).  
 
4.3.2 Vaccine handling  
Cool box temperatures were generally kept below 10˚C, although there was variation, 
with the standard vaccine having been kept at temperatures ranging from -18.8˚C to 
23.5˚C with median at 5.5˚C and the buffered vaccine kept at median temperature of 
4.5˚C (-17.6˚C to 22.8˚C). A graphic presentation of the cool box temperatures 
maintained by the teams is provided (Figure 4.1).  
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Table 4.2: General characteristics of the study animals  
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Figure 4.1: Cool box temperatures for the two teams sorted by increasing median temperatures. 
The red line indicates a temperature of 10°C.  
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Vaccination procedure and vaccine cool box used are shown (Figure 4.2a and 4.2b). 
Vaccines were used within 60 to 130 minutes post reconstitution with median at 95.5 
minutes for the standard vaccine and between 65 and 142 minutes with median of 95 
minutes for the buffered vaccine (Table 4.3). 
 
Table 4.3: Cool box temperature and vaccine use time  
 
Variable Median (Range) 
Temperature (°C) 
   Narok team 
   Naroosura team 
   Standard 
   Buffered 
 
3.8 (-7.8 to 23.5) 
6.6 (-18.8 to 19.3) 
5.5 (-18.8 to 23.5) 
4.5 (-17.6 to 22.8) 
Use time (minutes) 
   Narok team 
   Naroosura team 
   Standard 
   Buffered 
 
91.5 (69 to 142) 
95.0 (60 to 130) 
95.5 (60 to 130) 
95.0 (65 to 142) 
 
4.3.3 Description of adverse events  
In all vaccinates, 326 specific adverse events were reported, corresponding to a reporting 
rate of 4.1 cases per 1000 vaccinates within 100 days post-vaccination. ‘Swollen tail’ 
had the highest recorded incidence, corresponding to 3 cases per 1000 vaccinates whilst 
‘wounds at the perineal region’ was a rare adverse event corresponding to only 7 adverse 
events during the study period. In the subset, 18 specific adverse events were reported 
corresponding to 8.8 cases per 1000 vaccinates within 100 days post-vaccination. Again 
‘swollen tail’ had the highest recorded incidence, corresponding to 5.4 cases per 1000 


























a. the vaccination site; b. cool box with ice blocks, vaccine, syringe for vaccine reconstituting 
and data logger (yellow instrument); c. swollen tail; d. mild lesion at vaccination site; e. and f. 
necrotic and infected wound which may end up with slough-off of tail tip; g. tail-tip slough off; h. 
and i. Perineal involvement 
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Non-specific adverse events such as weakness, lameness, abortion and mortality were 
also recorded. A total of 160 non-specific adverse events were reported in all vaccinates, 
corresponding to a reporting rate of 2.1 cases per 1000 vaccinates within 100 days post-
vaccination. ‘Mortality’ had the highest incidence recorded, corresponding to 1 case per 
1000 based on all vaccinates. In the subset, 14 non-specific adverse events were reported 
corresponding to 7 cases per 1000 vaccinates within 100 days post-vaccination. 
‘Abortion’ had the highest incidence recorded for the subset, corresponding to 3.4 cases 
per 1000 vaccinates (Table 4.4). 
 
Table 4.4: Incidence of adverse events post-vaccination 
 
All vaccinates Subset Adverse event type 
Number 
(incidence per 1000) 
Number 
(incidence per 1000) 
i. Specific events     
    Swollen tail only 228  (2.9) 11  (5.4) 
    Tail slough only 81   (1.0) 4  (1.96) 
    Swollen tail and mortality 1  (0.01) 1  (0.49) 
    Swollen tail and lameness 2  (0.01) 0  (0) 
    Swollen tail and weakness 1   (0.01) 0  (0) 
    Swollen tail and tail slough 6  (0.1) 2  (0.98) 
    Perineal wound 7  (0.1) 0  (0) 
Subtotal 326  (4.1) 18  (8.8) 
     
ii. Non specific events     
    Mortality only 79  (1.0) 3  (1.5) 
    Abortion only 32  (0.4) 7  (3.4) 
    Lameness only 30   (0.4) 1  (0.5) 
    Weakness only 22  (0.3) 3  (1.5) 
Subtotal 160  (2.1) 14  (6.9) 
Total (i+ii) 486  (6.1) 32  (15.7) 
     
iii. Antimicrobial treatments 1018   (12.7) 33  (16.2) 
 
A total of 12.7 and 16.2 antimicrobial treatments per 1000 animals were recorded in all 
vaccinates and in the subset, respectively. Plotting the number of adverse events against 
time post-vaccination revealed a first peak of specific, non-specific and antimicrobial 
treatments within the first two weeks post-vaccination. The second peak of adverse 
events involving antimicrobial treatments and specific adverse events occurred between 





















































































adverse events and antimicrobial treatments was observed between 32-38 days post-
vaccination (Figure 4.3). 
 
Figure 4.3: Reported specific (black) and non-specific (green) adverse events and antimicrobial 













Tail diameter change was graphically presented and no difference in tail change was 
observed between vaccine types pre- and post-vaccination. Animals’ tail change for 
either vaccine type was normally distributed around zero (Figure 4.4). 
 
Figure 4.4: Tail change (diameter one month post-vaccination minus diameter pre-vaccination in 



















4.3.4 Univariable analysis of risk factors for specific and non-specific 
adverse events and of antimicrobial treatments  
Animals vaccinated with the buffered vaccine had higher odds of specific adverse events 
compared to animals vaccinated with the standard vaccine (P < 0.05). Female animals 
and animals vaccinated by the Naroosura team had significantly higher odds of specific 
adverse events compared to male animals and animals vaccinated by the Narok team (P 
<0.05). Animals from Osupuko had significantly more reports of specific adverse events 
compared to animals from Loita (P < 0.01) (Table 4.5a).  
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2.
 P-value indicated by superscript: ** P < 0.10 ** P < 0.05 *** P < 0.01. 
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The odds of non-specific adverse events in animals vaccinated with the standard and the 
buffered vaccine were not significantly different; similar results were observed in 
animals vaccinated by Narok and Naroosura teams. Young animals and those in fair 
body condition had significantly higher odds of non-specific adverse events than adults 
and animals in good body condition (P < 0.01) (Table 4.5b). 
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Animals vaccinated by the Naroosura team had higher odds of antimicrobial treatments 
than animals vaccinated by the Narok team (P < 0.01). Young animals (P <0.05) and 
animals from Osupuko (P < 0.01) had significantly more antimicrobial treatments than 
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Cross tabulation of independent variables revealed that Naroosura team was positively 
correlated with adult, female gender and negatively correlated with fair body condition 
score. Also, adult positively correlated to female and negatively correlated to fair body 
condition score’ (Table 4.6). 
 
 

















 2.05 15.40 2.56 2.73 
Team 
(Naroosura) 
0.15  327.52 92.11 3.5e+03 
Age (Adult) 0.00 0.00  1.2e+03 3.7e+03 
Gender 
(Female) 




0.10 0.00 0.00 0.01  
1
 Upper right half of the table shows Chi square statistic and lower left the p-values  
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4.3.5 Multivariable analysis of risk factors for specific and non-specific 
adverse events and of antimicrobial treatments post-vaccination  
Multivariable analysis of specific adverse events 
Animals vaccinated with the buffered vaccine had higher odds of specific adverse events 
compared to animals vaccinated with the standard vaccine. The effect of vaccine on the 
odds of specific adverse events was modified by ‘age’, ‘vaccinating team’, ‘gender’ and 
‘origin of animals’ (P < 0.01). The odds of specific adverse events in young animals 
vaccinated with either vaccine was similar whilst adults vaccinated with the buffered 
vaccine had increased odds of specific adverse events compared to adults vaccinated 
with the standard vaccine. The odds of specific adverse events in animals vaccinated 
with the buffered vaccine by the Narok team were higher than the odds of specific 
adverse events in animals vaccinated with the standard vaccine by the same team. The 
odds of specific adverse events were modified by gender. Odds of specific adverse 
events in male animals vaccinated with either vaccine were similar, whilst female 
animals vaccinated with the buffered vaccine had higher odds than female animals 
vaccinated with the standard vaccine. The odds of specific adverse events in animals 
from Osupuko vaccinated with the buffered and standard vaccine were higher than the 
odds ratio for animals originating from Loita and Mara vaccinated with either vaccine. 
Animals from Mara vaccinated with the standard vaccine had the lowest odds (Table 
4.7; model output in Appendix vi.). There was no evidence that the effect of the vaccine 
type on specific adverse events was modified by body condition score (results not 
shown). 
Multivariable analysis of non-specific adverse events 
The effect of the vaccine type on the odds of non-specific adverse events was 
significantly modified by the origin of animals (P < 0.10). Compared to animals 
originating from Osupuko that were vaccinated with the standard vaccine, animals 
originating from Osupuko that were vaccinated with the buffered vaccine had lower 
odds of non-specific adverse events. Compared to animals originating from Loita that 
were vaccinated with the standard vaccine, animals originating from Loita that were 
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vaccinated with the buffered vaccine had higher odds of non-specific adverse events 
(Table 4.7; model details in Appendix vii). The odds of non-specific adverse events in 
animals vaccinated with either vaccine were higher in animals originating from Mara 
than in animals from Loita and Osupuko.  
Multivariable analysis of antimicrobial treatments 
The effect of the vaccine on the odds of antimicrobial treatments was significantly 
modified by age (P < 0.10). In young animals, odds of antimicrobial treatments were 
higher for animals vaccinated with the standard vaccine than in animals vaccinated with 
the buffered vaccine. In adult animals, no effect of the vaccine on the odds of 
antimicrobial treatments was observed. Compared to young animals, adult animals 
vaccinated with either vaccine had lower odds of antimicrobial treatment (Table 4.7; and 
detailed in Appendix viii). The effect of the vaccine on the odds of antimicrobial 
treatments was not modified by body condition score, gender, vaccinating team and 
animal origin (results not shown).  
 
 
Table 4.7: Multivariable linear logistic mixed model based on specific, non-specific and 
antimicrobial treatments adverse events 
 




Specific adverse events  
Vaccine type 0.0019 0.0028 
Young animals 0.0027 0.0027 
Adult animals 0.0017 0.0029 
Narok 0.0015 0.0028 
Naroosura 0.0022 0.0027 
Male 0.0017 0.0019 
Female 0.0020 0.0032 
Loita 0.0011 0.0026 
Mara 0.0010 0.0020 
Osupuko 0.0047 0.0051 
Non-specific adverse events 
Vaccine type 0.001 0.001 
Loita 0.0007 0.0008 
Mara 0.0014 0.0014 
Osupuko 0.0010 0.0007 
Antimicrobial treatment 
Vaccine type 0.009 0.010 
Young animals 0.0117 0.0109 
Adult animals 0.0081 0.0094 
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4.4 Discussion and conclusion 
4.4.1 Discussion 
A vaccine safety trial based on T1/44 buffered vaccine has not been reported before. 
Limited safety trials have been reported based on the standard vaccine. This is the first 
study in which adverse events post CBPP vaccination have been systematically 
monitored and classified as specific and non-specific. Generally, herders in the study 
area did not seem to worry much about adverse events post-vaccination. During the 
cross-sectional study (Chapter 2), it was revealed that herders were aware of post-
vaccination adverse events (both specific and non-specific) but they valued vaccination 
as a major control method against the disease. Additionally, herders indicated that post-
vaccination adverse events were successfully managed by the use of antimicrobials.  
 
The incidence of adverse events in the current study is similar to that reported by Sori 
(2005). However, Daleel (1971) reported very low incidence with only two cases out of 
86,035 vaccinates in Sudan. The lower incidence reported in the Sudan trial might be 
due to a difference in the vaccine used. The T1/44 broth vaccine was used in the trial 
carried out in Sudan; this particular vaccine has been reported to have low incidence of 
adverse event post-vaccination (Karst, 1971). The incidence reported in our study is 
lower than reported in Zambia  (Revell, 1973). Revell (1973) reported tail-tip slough off 
incidence of 12% (corresponding to 120 cases per 1000 vaccinates) based on 6,673 
animals vaccinated from ‘infected’ areas which was higher than the incidence of 0.17% 
(corresponding to 2 cases per 1000) reported in “uninfected” areas. The author suggested 
a possibility of biased attendance of herders with animals that had experienced tail-tip 
loss, because of the promise of free treatments for any adverse reaction following second 
vaccination. 
 
Changes in tail diameter measurements were used as a tool in assessing tail swelling 
post-vaccination. The tail changes for animals vaccinated with either vaccine were 
normally distributed around the mean zero indicating no difference. The same tool was 
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used in the trial carried out in KARI, Muguga and it proved to be useful when tail 
measurements were recorded daily for the first 30 days post-vaccination (Wesonga, H. 
and Schnier, C. (2009) personal communication). Tail swelling was mostly observed in 
the first two weeks post vaccination in the trial at KARI. Failure to find a difference in 
tail swelling in my field trial may be due to a long interval between readings but 
measurement error could also play a role.  
 
A number of non-specific adverse events (death, abortion and lameness) were reported 
by herders to be associated with CBPP vaccination. In our study, 1 death per 1000 
vaccinates was observed based on all vaccinates and 1.5 per 1000 vaccinates based on 
the subset. Mortality reported in our study was similar to mortality reported by Sori 
(2005). Much higher incidence of 1% corresponding to 10 adverse events per 1000 
vaccinates based on a crude vaccine was reported by Louis Willems, which prompted a 
search for safer vaccines  (Huygelen, 1997).  
 
Three peaks of adverse events (specific, non-specific and antimicrobial treatments) were 
observed based on the subset. In the first peak, specific, non-specific and antimicrobial 
treatments were all recorded at high incidence, although antimicrobial treatments had the 
highest incidence. This could be related to increased reports of diseases such as 
ephemeral fever coinciding with vaccination. The second peak involved specific adverse 
events and antimicrobial treatments; the third peak of adverse events was observed 
between 32-38 days post-vaccination and all adverse events (specific, non-specific and 
antimicrobial treatments) were at high incidence. The third peak of events coincided 
with the follow up visit by a bleeding team which suggest a possibly of reporting bias. 
 
Field vaccine handling has been reported as an important aspect in assuring viability of 
the live vaccines. In our study, vaccine handling was assessed based on the maintenance 
of cool box temperatures below 10˚C and use of the reconstituted vaccine within 2 
hours. The 10˚C temperature cut off was selected because it was thought to be within the 
range of recommended vaccine storage temperature of 4˚C and 23˚C which also 
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revealed good maintenance of vaccine viability in a trial (Ngbede et al., 1994). 
Generally, the cool box temperatures were maintained below 10˚C and median vaccine 
use time was within the recommended time. However, there were several occasions 
when the temperature and use time conditions were not met. This suggests that there is a 
need for vaccination teams to have a plan of assessing if the guidelines on the use of 
vaccine are being adhered to. Vaccine titres were not evaluated during use and it is 
unknown whether prolonged use or high cool box temperatures actually affected 
viability of the vaccine. 
 
The result shows that the buffered vaccine was associated with increased odds of 
specific adverse events when compared to the standard vaccine. The effect of vaccine on 
specific adverse events was modified by age (age was also correlated to gender and body 
condition) of the animal. The results show increased odds of specific adverse events in 
young animals vaccinated with either vaccine. Increased specific adverse events in 
young animals was also reported in a study carried out in Zambia based on the standard 
vaccine  (Revell, 1973). The results also indicate that adult animals vaccinated with the 
buffered vaccine had increased odds of specific adverse events compared to adults 
vaccinated with the standard vaccine. Lower odds observed in adults vaccinated with the 
standard vaccine could suggest that the animals had previously been exposed to the same 
vaccine type. Age could be a proxy for accumulated exposure to CBPP vaccination or 
outbreak. It is possible that a previously exposed animal will have antibodies against 
Mycoplasma that neutralizes the live vaccine stain, resulting in low reactivity  (Siegrist, 
2007). Revell (1973) observed that adverse events were significantly reduced post 
second vaccination.  
 
The result of the study shows that the odds of specific adverse events in young animals 
vaccinated with either vaccine is similar. This is consistent with the findings of the 
safety trial carried out at KARI, Muguga to compare the standard with the buffered 
vaccine. For the KARI trial, young and unexposed animals were recruited and no 
significant differences in tail swelling (specific adverse events) between the two 
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vaccines were observed (Schnier C. (2009) personal communication). The lack of 
evidence for a vaccine effect could also be attributed to short vaccine use time post 
reconstitution and small sample size in the KARI trial. If vaccine is used within a short 
time, as in the KARI trial, there would not be enough time for an effect of the buffer on 
vaccine survival to become manifest. 
The effect of the vaccine on the odds of specific adverse events was modified by the 
origin of animals, with animals from Osupuko developing more specific adverse events 
than animals from Loita and Mara. The cross sectional study (Chapter 2) revealed that 
herders in Mara reported a higher frequency of both CBPP outbreaks and vaccinations 
than herders from Loita. Based on the vaccination survey, herders from Osupuko that 
participated in the safety study did not report CBPP outbreaks or vaccinations in the past 
ten years. It is therefore possible that animals from Osupuko experienced a higher 
incidence of specific adverse events compared to animals from Mara and Loita because 
they had no previous exposure to the organism.  
 
Despite the effect of vaccine depending on age, gender and animal origin, the buffered 
vaccine was consistently associated with a higher incidence of specific adverse events 
than the standard vaccine. The reasons for specific adverse events post-vaccination have 
not been elucidated. Sori (2005) concluded that adverse events were a consequence of 
improper vaccine handling and injection technique. However, according to Revell 
(1973), it was found that changing the vaccination needle after every 10 animals did not 
result in a significant change in the incidence of adverse events. In the controlled 
vaccine trial conducted in KARI it was observed that animals vaccinated with either 
standard or the buffered CBPP vaccine had significantly increased tail swelling 
compared to control animals (animals inoculated with PBS or normal saline alone) 
(Wesonga, H. and Schnier C. (2008) personal communication). Possibly, CBPP post-
vaccination local adverse events are associated with MmmSC residual pathogenicity 
since the vaccines are based on live organisms. In a different study, Mycoplasma T1 
vaccine strain was isolated from a skin lesion post-vaccination and identified based on 
PCR  (Wesonga and Thiaucourt 2000), demonstrating that the vaccine strain could be 
 
 128 
associated with specific adverse events. Therefore, the increase in incidence of specific 
adverse events could be associated with a stable vaccine titre in the buffered formulation 
as compared to the standard vaccine. However, vaccination tires were not evaluated in 
my study. The withdrawal of KH3J on the basis of being less immunogenic and without 
post-vaccination adverse events  (Rweyemamu et al., 1995) matches the belief by 
scientists in the 1940’s that local reaction was a proof of vaccine viability  (Mowat and 
Rweyemamu, 1997). 
 
Based on the multivariable model, occurrence of non-specific adverse events did not 
depend on the age or body condition of an animal. However, the effect of vaccine on the 
odds of non-specific adverse event was significantly modified by origin of animals. 
Non-specific adverse events could be related to other factors or diseases specific to the 
origin. It was not clear how area specific factors could influence vaccine effect. Sori 
(2005) observed difference in post-vaccination adverse events (specific and non-
specific) in the zones studied. Poor body condition of vaccinated animals in one zone 
was suggested to be associated with increased incidence of adverse events.  
 
Based on the multivariable model, young animals vaccinated with either vaccine had 
higher odds of antimicrobial treatments than adult animals. This finding may suggest 
that antimicrobials were used in the susceptible group to treat both specific and non-
specific adverse events. Antimicrobial treatments have been recommended in treating 
local adverse events post CBPP vaccination  (Mowat and Rweyemamu, 1997). Increased 
antimicrobial treatments in animals with adverse events were reported in Ethiopia, 
where timely treatments were responsible for decreased case-specific mortality  (Sori, 
2005). However, our study showed higher incidence of antimicrobial treatments than of 
specific and of non-specific adverse events combined. In our study population, 
antimicrobial treatments were very common and we suspect that antimicrobial 
treatments post-vaccination were not restricted to treating adverse events post-
vaccination but also included treatments for other bacterial and secondary bacterial 
infections following protozoan or viral diseases prevalent in the area. Indeed, during the 
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follow up period diseases such as ephemeral fever, trypanosomosis, East Coast Fever, 
anaplasmosis, babesiosis and Foot and Mouth Disease were reported  
4.4.2 Conclusion 
The current study shows that both the standard and the buffered vaccines gave rise to 
adverse events post-vaccination. However, the buffered vaccine was associated with an 
increased risk, which appeared to be influenced by previous exposure as expressed by 
age and origin of the animal. The difference between the two vaccines was significant 
when the vaccines were used over a longer period. The new vaccine was developed 
based on the expectation that the buffer system would help to maintain a high vaccine 
titre during use. The observed difference, combined with the underlying theory, thus 
suggests that the amount viable MmmSC may have a role to play in the post-vaccination 
adverse events. Since increased odds of specific adverse events might be related to 
enhanced efficacy, which is also thought to be due to increased viability of MmmSC, it is 
emphasized that when developing more efficacious CBPP vaccines, vaccine safety 
should be given due consideration. 
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Chapter 5 - A comparative CBPP vaccine efficacy estimation 
based on a field trial carried out in south-western Kenya 
Abstract 
A double-blind CBPP vaccine trial was carried out among 79,959 cattle in 458 herds in 
Loita, Mara and Osupuko divisions of Narok District, Kenya, between February 2007 
and March 2008. The objective of this study was to compare period prevalence of 
clinical signs suggestive of CBPP (coughing and laboured breathing) and seroconversion 
post vaccination in cattle vaccinated with either a standard CBPP-vaccine  (Contavax®), 
currently used in Kenya for control of CBPP or a buffered vaccine manufactured 
according to suggestions of March  (2004). 
 A total of 164 animals out of 79,959  (0.21%) were reported showing clinical 
signs suggestive of CBPP, while 32% of cattle in a subset of 1827 cattle seroconverted 
within 3 months post vaccination. Compared to animals vaccinated with the buffered 
vaccine, animals vaccinated with the standard vaccine had increased odds of showing 
clinical signs and lower odds of seroconversion post vaccination. The effect of the 
vaccine on the odds of showing clinical signs was modified by age, gender and origin of 
animals.  
 Interpretation of the results of our study is not straightforward because it is not 
known whether the animals that seroconverted post vaccination were the same animals 
that were protected against developing respiratory signs suggestive of CBPP positive. 
Since the buffered vaccine was additionally associated with increased odds of specific 





5.1 Introduction  
CBPP control has been based on vaccination and animal movement control. Vaccination 
initially was based on broth T1 (1920’s to early 1970’s) vaccine (Davies et al., 1968; 
Gilbert et al., 1970) which was later replaced by freeze dried live attenuated MmmSC 
vaccine T1/44 vaccine (OIE, 2008). A streptomycin variant (T1sr) was developed and 
used in combination with Rinderpest vaccine (Rweyemamu et al., 2000). Observations 
from CBPP outbreaks in the 1990s indicated that the T1sr  vaccine had failed to protect 
cattle against the disease in Botswana (Amanfu et al, 1998; Thiaucourt et al, 2000). 
Failure to protect was attributed to sub-optimal titres of viable MmmSC in the vaccine. 
According to OIE, CBPP vaccine should have at least 108 CFU per dose (OIE, 2004). 
Previous studies have indicated that lower titres (105 CFU per dose) were not protective 
but vaccine titres from 107 and above were protective (Gilbert and Windsor, 1971).  
Low vaccine titres have been attributed to low viability of the vaccine culture caused by 
metabolism of glucose in standard Mycoplasma growth media (Gourlay’s)  (Windsor, 
1978), which results in a drop in pH to values below the optimum of 7.4  (Gourlay and 
MacLeod, 1966). To prevent the drop in pH and thereby increase viability and vaccine 
efficacy, inclusion of a buffer system based on 4- (2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) to standard Gourlay’s culture media has been 
suggested. In the experiment reported by Waite and March, 2001 it was observed that 
the pH of standard media (unbuffered) dropped from 7.4 to 5.5 during growth, and this 
decline was mirrored by a rapid drop in titre from 1010 per ml to completely inactivated 
within 2 days at 37◦C. However, the pH of HEPES-buffered media dropped from 8.0 to 
7.1 during growth, and both the final bacterial titre and culture survival were increased 
compared to standard media; maximum titre was at least one log10 higher and 
maintained above 108 after a month kept at 37◦C.  To give additionally buffering effect, 
reconstitution with phosphate buffered saline was suggested (March, 2004). 
 
CBPP vaccine efficacy under field conditions has not been evaluated in a pre-planned 
and systematic manner. The current study compared two vaccines, a standard vaccine 
(Contavax®) currently used in Kenya for control of CBPP and a buffered vaccine 
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manufactured according to the suggestions of March (2004). It was hypothesized that 
inclusion of a buffer-system to both growing media and diluent would result in increased 
survival of MmmSC, and thereby higher vaccine protection. The aim of this study was to 
compare  
 
i. Prevalence of clinical signs suggestive of CBPP in cattle vaccinated with 
either of the vaccines within a year post vaccination  
ii. Seroconversion in cattle vaccinated with either of the vaccines within 3 
months post vaccination  
 
In addition, detailed outbreak investigations were carried out upon receipt of a report of 
the death of an animal with clinical signs and post mortem lung lesions suggestive of 




5.2 Materials and methods 
5.2.1 Study area and design 
 
A cohort study designed to compare efficacy of the standard vaccine with the buffered 
vaccine was carried out between February 2007 and February 2008. The study involved 
animals from Loita, Mara and Osupuko divisions of Narok south district, Kenya (Figure 










5.2.2 Vaccines and vaccination  
Both vaccines were based on freeze dried live attenuated MmmSC T1/44 and were 
manufactured by the Kenya Agriculture Research Institute - Veterinary Vaccine 
Production Centre (KARI-VVPC) in Nairobi. They differed in that the standard vaccine 
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was cultured in un-buffered growth media and was reconstituted with normal saline 
while the buffered vaccine was cultured in HEPES-buffered growth media and 
reconstituted with phosphate-buffered saline (PBS).  
 
Vaccination was carried out at 19 crushes selected from 38 listed in the three divisions. 
Two teams, one from the Narok District Veterinary Office and one from the Naroosura 
Agro-Vet Services, were involved in the vaccination. At the crush, group of 20-30 
animals were assigned alternately to either standard or buffered vaccine and all 
vaccinates were ear-tagged to enable identification during follow-up visits. All animals 
within a herd were vaccinated and effort was made to vaccinate 50% with each vaccine. 
Unvaccinated animals and animals with unknown vaccine status could enter the herd 
during the follow-up period due to purchases, tribal exchanges and births.  
5.2.3 Monitoring for clinical signs  
Monitoring was carried out by trained community animal health workers for a period of 
one year post vaccination. To record all diseases, animals were monitored weekly during 
the first month post vaccination and then monthly thereafter (Appendix 4). Clinical signs 
suggestive of CBPP, which herders were capable of recognizing (Zessin et al., 1985), 
were ‘laboured breathing’ and ‘coughing’. Because cattle could have been showing any 
of those clinical signs even before vaccination, a period prevalence rather than an 
incidence of clinical signs was estimated In addition to recording clinical signs, detailed 
outbreak investigations were carried out upon receipt of a report of the death of an 
animal with clinical signs and post mortem lung lesions suggestive of CBPP  (a firm 
discoloured lung with marbled appearance and a chest cavity filled with yellowish fluid;  
(FAO, 2002)). Outbreak investigations were carried out by the author and/or the district 
veterinary officers within a week after receipt of the report and involved clinical 
examination and bleeding of all animals that shared the same boma. Serum samples 
were processed and tested using the cELISA kit developed by CIRAD-EMTV (detailed 
in Chapter 2. 
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5.2.4 Selection of subset monitored for seroconversion 
To compare the effect of the vaccines on seroconversion, 2400 animals were recruited as 
a subset from the study population. The sample size of the subset was calculated using 
equation [1]  
 










n                           [1] 
 
where n = sample size for each group; ρ1 = seroconversion in standard group (0.20); ρ2 = 
seroconversion in buffered group (0.25); ρ= (ρ1+ ρ2)/2=0.225; Mα/2 = multiplier 
associated with 95% CI (1.96); Mβ = multiplier associated with β probability of type II 
error (0.84)  (Thrusfield, 2005). 
The estimate for the seroconversion in cattle vaccinated with the standard vaccine was 
based on a study in an endemic area (Provost et al., 1987). A 5% difference in 
seroconversion between the two vaccines was chosen to detect a relatively small 
improvement in vaccine efficacy. The formula indicated a sample number of 1092 
animals per vaccine; however, the number was increased to 1200 animals per vaccine to 
compensate for any withdrawals and losses to follow-up. Animals were recruited from 
60 herds selected on the basis of the herders’ willingness to comply with bleeding 
schedules and regular visits as per protocol of the study. From each herd, 40 animals 
were selected purposefully to include 20 animals per vaccine type and to include cattle 
of all sex and age groups. Animals were bled pre-vaccination and approximately one 
month and three months post vaccination. Bleeding and sera storage was carried out as 
detailed for the cross sectional study (Chapter 2). Serum samples were tested using a 
commercially available competitive ELISA (CIRAD-EMTV) test. An animal was 
regarded to have seroconverted if it was seronegative (percent inhibition (PI) <50) pre-




Descriptive statistics were carried out using statistical package STATA (Intercooled 8th 
version; StataCorp, Texas, USA). Outcome variables were clinical signs suggestive of 
CBPP (Yes/No) based on all vaccinates; seroconversion post vaccination (Yes/No) 
based on the subset and testing positive in a cELISA (Yes/No) and clinical signs 
suggestive of CBPP (Yes/No) based on the detailed outbreak investigation. Separate 
models were developed for each outcome. Clinical signs and seroconversion were 
analysed using generalized linear mixed models (GLMM) with ‘herd’ and ‘crush’ 
included as random effects. Testing positive in a cELISA and clinical signs suggestive 
of CBPP post ‘outbreak’ were analysed using GLMM with boma included as a random 
effect. Data were analysed using GenStat Release 10.2 (Lawes Agricultural Trust, 
Rothamsted Experimental Station).  
Because the objective of the analysis was to compare the two vaccines, the variable 
relating to the type of vaccine was the only independent variable maintained in all 
models. To test whether the effect of the vaccine was modified by other variables, 
interaction terms were added. A detailed description of variables included in the analysis 
is given in Table 5.1.  
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Table 5.1: Description of variables included in the models 
 
Dependable variable Description 
Age  Age in years categorized  (Young: ≤3 yrs; Adult: >3 yrs) 
Herd Group of animals vaccinated under one herder name 
Body condition Body condition score  (Good; Fair) 
Crush Loita: Enkoseremai, Entasekera, Morijo, Nkopon, Olmesutie and 
Olorte. 
Mara: Sekenani, Oldisare, Oloonchora, Ololturoto, Olpusimoru, 
Orkinyei and Talek. 
Osupuko: Elang’ata Enterit, Naroosura, Nkimpa, Ntuka, Olepariata 
and Oloigeruno. 
Division Administrative unit  (Loita; Mara; Osupuko) 
Gender  Animal gender  (Male; Female) 
Team  Vaccine delivery team for an individual animal  (Narok; Naroosura) 






5.3.1 General description of study animals 
In total, 79,959 animals from 458 herds were vaccinated against CBPP; 49.1% were 
administered with the standard vaccine and 50.9% with the buffered vaccine. In both 
cohorts, most animals were Zebu type and in good body condition (Table 5.2).  
In the subset, 2038 animals were included, of which 211 tested cELISA positive pre-
vaccination and were therefore omitted from analysis. Of the 1827 remaining animals, 
949 (51.9%) were vaccinated with the standard vaccine and 878 (48.1%) with the 
buffered vaccine (Table 5.2).  
 
A total of 293 animals belonging to four bomas with suspected outbreaks of CBPP were 
included in the outbreak investigations. Of these, 141 were vaccinated with the standard 
vaccine and 152 with the buffered vaccine (Table 5.2). Several animals with unknown 
vaccine history were excluded from analysis. All bomas included in the outbreak 
investigation were from Mara division and had been vaccinated by the Narok team. 
 
Table 5.2: General characteristics of the study animals 
 
Variable Variable levels 
  
Number of cattle 
(%) 
All vaccinates 
Number of cattle 
(%) 
Subset 
Number of cattle 









  (34.7) 


















  (92.4) 















  (31.9) 










Age  Young ≤3 years 













Breed Zebu crosses  
Zebu 
 469  
79,490  
   (0.6) 
  (99.4) 
19  
1,808 










  (52.6) 












  (49.1) 












5.3.2 Univariable analysis based on clinical signs suggestive of CBPP (all 
vaccinates)1 
A total of 164 animals out of 79,959 (0.21%) were reported showing clinical signs of 
coughing and laboured breathing during the follow-up period of one year. The period 
prevalence of clinical signs suggestive of CBPP was not significantly different between 
the two vaccines (OR of buffered vaccine vs. standard = 0.81). Compared to animals 
from Loita, animals from Mara had significantly higher period prevalence (P <0.01) 
whilst those from Osupuko had a significantly lower period prevalence. Compared to 
animals vaccinated by the Narok team, animals vaccinated by the Naroosura team had 
significantly higher prevalence (P <0.01) (Table 5.3).  
 
                                                 
1 Vaccine used in the current study were produced based on Standard Operation Procedures for quatity production of 
CBPP vaccines and OIE guidelines and Author was adviced that both vaccine had titre that met minimum standard 








 Signs incidence 
 (95%CI)
2 
Odds Ratio  
 (95% CI)
2 
Clinical signs  79,959 0.21 (0.17-0.24)  
Age  
   Young 











   Good 











   Loita 
   Mara 














   Male 











   Narok 










Vaccine type   
   Standard   












 number of animals monitored 
2.
 P-value indicated by superscript: ** P < 0.10 ** P < 0.05 *** P < 0.01. 
 
In the first month post vaccination, the cumulative period prevalence was similar 
between the two vaccine types. Thereafter, animals vaccinated with the standard vaccine 
had higher prevalence compared to animals vaccinated with the buffered vaccine (Figure 
5.2). 
5.3.3 Univariable analysis based on seroconversion post-vaccination  
In the subset, 32% of vaccinated animals seroconverted within the first 3 months post 
vaccination. Seroconversion of animals vaccinated with the standard vaccine was 28%, 
which was significantly lower than the 36% seroconversion of animals vaccinated with 
the buffered vaccine (P <0.01). Compared to animals vaccinated with the standard 
vaccine, more animals vaccinated with the buffered vaccine had seroconverted one 
month post vaccination. At three months post vaccination seroconversion was similar 




Figure 5.2: Cumulative period prevalence of clinical signs suggestive of CBPP (lines) and 





















Compared to animals that were vaccinated by the Naroosura team, significantly more 
animals vaccinated by the Narok team seroconverted (P <0.01). Animals from Mara had 
significantly higher seroconversion compared with animals from Loita, (P <0.05) (Table 
5.4). 
Cross tabulation of independent variables revealed that Naroosura team was positively 
correlated with adult, female gender and negatively correlated with fair body condition 












Odds Ratio  (95% CI)
3 
Overall seroconversion 1,827 31.96 (29.82-34.11)  
Vaccine type 
   Standard 











   Narok  











   Young 











   Good 











   Male 











   Loita 
   Mara 















 animals were selected from the vaccinates for bleeding 
2.
 animals that were negative at baseline but positive at first or second bleeding post 
vaccination 
3.
 P-value indicated by superscript: * P < 0.10, ** P < 0.05, *** P < 0.01. 
 
5.3.4 Univariable analysis based on detailed outbreak investigation subset 
In herds suspected of having an outbreak of CBPP, 17% of cattle tested positive using 
the cELISA. Compared to animals vaccinated with buffered vaccine, animals vaccinated 
with the standard vaccine had a higher seroprevalence; however, this difference was not 
significant. In the same herds, approximately 6% of vaccinated animals were observed 
with clinical signs suggestive of CBPP. Compared to animals vaccinated with the 
buffered vaccine, animals vaccinated with the standard vaccine had higher prevalence of 





Table 5.5: Univariable analysis of cELISA and clinical signs based on outbreak subset 
 
Variable Number Seroprevalence 
 (95%CI) 
Odds Ratio  
 (95% CI) 
% Signs 
 (95%CI)  
Odds Ratio  
 (95% CI) 
  cELISA Clinical signs 
Animals 293 17.41 (13.04-21.77)  5.80 (3.11-8.49)  
Age  
   Young 

















   Good 

















   Male 

















   Standard 


















5.3.5 Multivariable model based clinical signs suggestive of CBPP (all 
vaccinates) 
Compared to animals vaccinated with the buffered vaccine, those vaccinated with the 
standard vaccine had a higher prevalence of clinical signs suggestive of CBPP. The 
effect of the vaccine on the prevalence was modified by the age, gender, body condition 
and origin of vaccinates. In the young group, cattle vaccinated with the standard vaccine 
had a higher prevalence of clinical signs compared to cattle vaccinated with the buffered 
vaccine; in the adult group, the prevalences were not different. Male cattle vaccinated 
with the standard vaccine had a higher prevalence of clinical signs when compared to 
cattle vaccinated with buffered vaccine; in female animals, the prevalences were not 
different. Finally, animals from Mara vaccinated with either vaccine had a higher 
prevalence of clinical signs when compared to cattle vaccinated with either vaccine from 
Osupuko and Loita. Animals from Osupuko vaccinated with the buffered vaccine had 
the lowest prevalence of clinical signs. There was no evidence that the effect of vaccine 
on the prevalence of clinical signs was modified by the vaccinating team (Table 5.6; 
detailed in Appendix ix.). 
5.3.6 Multivariable model based on seroconversion post vaccination  
Compared to animals vaccinated with standard vaccine, those vaccinated with the 
buffered vaccine had increased odds of seroconversion post vaccination (P <0.01). There 
was no evidence that the effect of vaccine on seroconversion was modified by 
vaccinating team, age, gender or body condition of the animal (Table 5.6: detailed in 




Table 5.6: Multivariable linear logistic mixed model based on all vaccinates and subset 
 










Buffered vaccine  
Odds  
 Clinical signs based on all vaccinates Seroconversion based on subset 
Vaccine type 0.41 0.31 0.27 0.36 
Young animals 0.60 0.28 0.26 0.32 
Adult animals 0.34 0.31 0.28 0.38 
Male 0.45 0.19 0.24 0.32 
Female 0.38 0.36 0.29 0.38 
Good 0.39 0.31 0.28 0.38 
Fair 0.49 0.15 0.24 0.24 
Loita 0.51 0.38 0.26 0.37 
Mara 0.90 0.95 0.35 0.40 
Osupuko 0.17 0.08 0.22 0.31 
Narok 0.30 0.24 0.30 0.42 
Naroosura 0.54 0.56 0.25 0.31 
 
  
5.3.7 Multivariable model based on detailed outbreak investigation 
After correcting for the effect of ‘enclosure’, the model showed that, compared to 
animals vaccinated with the buffered vaccine, animals vaccinated with standard vaccine 
had significantly increased odds of testing cELISA-positive in herds suspected of having 
an outbreak of CBPP  (P <0.10). There was no evidence that the effect of vaccine on the 
odds of testing cELISA-positive was modified by age, gender or body condition of the 
animal (Table 5.7; detailed in Appendix 3a). There was no evidence that the effect of 
vaccine on clinical signs was dependent on vaccine type, age, gender and body condition 
(Table 5.7; detailed in Appendix xi). 
 
Table 5.7: Multivariable linear mixed model based on detailed outbreak investigation  
 
Variables Standard vaccine 
Odds  




Buffered vaccine  
Odds  
 Seroprevalence based on cELISA Clinical signs 
Vaccine type 0.22 0.13 0.05 0.04 
Young animals 0.19 0.05 0.08 0.04 
Adult animals 0.23 0.18 0.04 0.04 
Male 0.22 0.11 0.14 0.06 
Female 0.21 0.14 0.03 0.03 
Good 0.25 0.16 0.06 0.04 




5.4 Discussion and conclusion 
5.4.1 Discussion 
Vaccine efficacy studies have traditionally been carried out under controlled conditions 
(Thiaucourt et al., 2000; Masiga and Windsor 1974; Hudson and Turner, 1963). Field 
trials designed to assess CBPP vaccine efficacy are rare but analogous studies have been 
reported for other Mycoplasma diseases. For example, the efficacy of a single-dose of 
Mycoplasma hyopneumoniae vaccine was evaluated in 3 to 5 week old pigs. Vaccination 
was associated with significantly lower percentage of lung lesion scores  (Dawson et al., 
2002) compared to the controls. My field study on CBPP vaccine efficacy is based on 
period prevalence of clinical signs suggestive of CBPP and seroconversion post 
vaccination.  
The results from my study suggests greater clinical protection of cattle vaccinated with 
the buffered vaccine, with animals vaccinated with the standard vaccine showing a 
higher prevalence of clinical signs suggestive of CBPP. Improved clinical protection by 
the buffered vaccine could be related to stable viability of MmmSC resulting from the 
use of buffering systems at vaccine production and field application stages (March, 
2004; Waite and March). However this is extrapolation from results from Waite and 
March (2001) because vaccine titre evaluation during use was not carried out. The 
vaccine effect on clinical signs was modified by age, gender and origin of animals. As 
buffering the vaccine may enhance vaccine titre, this observation suggests that 
unexposed animals (younger animals and animals from Loita and Osupuko) may require 
a relatively higher titre of vaccine to mount a protective immune response compared to 
animals that have had chance of being exposed to CBPP e.g. older animals and those 
from Mara. Therefore, by maintaining the vaccine titre, improvements in vaccine 
efficacy would be more evident in naive than in exposed animals.  
 
The current study suggests that vaccination with the buffered vaccine was associated 
with reduced clinical signs suggestive of CBPP. The use of respiratory signs as indicator 
for clinical CBPP may have been aspecific, because coughing and difficult breathing are 
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not related to CBPP only but also to other diseases endemic in the study area, such as 
East Coast Fever and Ephemeral fever. Detailed information on differential diagnosis of 
CBPP is provided elsewhere (FAO, 2002).  
 
Higher odds of seroconversion in animals vaccinated with the buffered vaccine 
compared to animals vaccinated with the standard vaccine was observed and suggested 
that the vaccine effect was not modified by vaccinating team, age, body condition, 
gender or origin of the animals. These results conflict with those of a controlled trial 
carried out at KARI-Muguga, which showed no evidence of any effect of the type of 
vaccine on seroconversion (Wesonga, H. and Schnier, C. personal communication). The 
difference between these two studies could result from variation in the time between 
reconstitution of the vaccine and vaccination. In the controlled trial, the vaccine was 
used within 20 minutes post reconstitution (Wesonga, H. personal communication), 
which was too short for the effect of the buffer to be observed. In the field trial, vaccines 
were used within an average of 95 minutes post reconstitution. In addition, 30 animals 
per group were used in experimental trial at KARI, which might not have been enough 
to detect small vaccine improvements.  
 
The results from the current study indicate that increased odds of seroconversion post 
vaccination for cattle vaccinated with the buffered vaccine were only seen one month 
post vaccination; the difference was very small 3 months post vaccination. Interestingly, 
reduced prevalence of clinical signs suggestive of CBPP for cattle vaccinated with the 
buffered vaccine were only seen later than one month post vaccination. The higher 
seroconversion associated with buffered vaccine preceded the reduced clinical signs. 
This might be taken as evidence that seroconversion enhanced the difference in 
reporting of clinical signs between the vaccines. 
 
Based on the detailed outbreak investigations, 17% of cattle tested cELISA-positive in 
herds suspected of having an outbreak of CBPP. Compared to animals vaccinated with 
the buffered vaccine, animals vaccinated with the standard vaccine had increased odds 
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of testing positive. However, because it is not clear whether testing positive indicates 
vaccine success (seroconversion due to vaccination) or failure (seroconversion due to 
infection despite vaccination), interpretation of these results is difficult. This finding re-
enforces the view that serodiagnosis is a challenge in areas where vaccination is being 
practiced (Chapter 2). It also highlights the importance of DIVA vaccines.  
 
The current study shows that vaccination with the buffered vaccine was associated with 
increased seroconversion, reduced clinical signs and reduced seroprevalence post 
outbreak. However, interpretation of this result should be guarded, because it is not clear 
whether the animals that seroconverted post vaccination were the same animals that 
were protected against developing respiratory signs suggestive of CBPP and against 
testing positive post ‘outbreak’. Therefore care should be taken to avoid ecological bias, 
which occurs when an association observed at a group level does not necessarily 
represent an association that exists at an individual level.  
5.4.2 Conclusion 
Generally, the current study shows that the buffered vaccine was associated with a 
reduction in clinical signs suggestive of CBPP and an increase in seroconversion post 
vaccination. Our findings are consistent with the hypothesis that buffering results in 
increased survival of the MmmSC, contributing to increased seroconversion, decreased 
clinical cases post vaccination and low seroprevalence post ‘outbreak’.  
 
Development of a DIVA vaccine might be an option to enhance differentiation of 
vaccinated from infected animals. In addition, since improved vaccine viability might 
have been associated with increased adverse events post vaccination; there is a need for 
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Chapter 6 – Discussion and outlook 
6.1 General discussion 
CBPP control in Europe, the USA and Japan was possible through stamping out and 
strict control of animal movement (Masiga et al., 1996; Rweyemamu and Benkirane, 
1996; Provost et al., 1987). Among African countries that reported CBPP in the 1990s, 
only Botswana managed to eradicate CBPP, based on a stamping out policy (Amanfu et 
al., 1998). CBPP control based on stamping out is an expensive policy to implement and 
not many African countries can afford it because of economic constraints. Most African 
countries allocate less than 10% of national budgetary resources to agriculture and rural 
development and only part of those resources is allocated specifically for animal disease 
control programmes (ftp://ftp.fao.org/unfao/bodies/arc/23arc/; last accessed on 16th April 
2009). In other countries, such as Portugal, test and cull was practiced in addition to 
strict cattle movement control  (FAO, 2006). A testing-based policy, however, would be 
challenging to implement in CBPP-endemic countries of Africa where vaccination has 
been practiced for the past twenty years or more. It was observed that CBPP vaccination 
was partly responsible for seropositivity (Chapter 2), suggesting that the OIE-
recommended serological tests were unable to differentiate vaccinated and infected 
animals. Therefore, implementation of a testing-based policy would require improved 
diagnostic tests that can differentiate vaccinated from infected animals. CBPP control by 
vaccination also requires strict control of animal movement (FAO-2002). In Namibia, it 
was observed that vaccination and movement control resulted in drop of both morbidity 
and mortality (Bamhare and Kohrs 2000). Combination of strategies is important 
because vaccine efficacy is less than 100%. Combination of strategies would limit the 
risk of disease introduction as well as the risk of disease spread if introduction happened. 
However, animal movement control is difficult to enforce in pastoral systems because 
transhumance is a coping strategy practiced during the dry season. Most of the 
respondents in the cross-sectional study had their animals mixing with other herds 
during grazing and watering and at salt lick points. More than 75% of respondents 
brought in animals through gifts, dowry or purchases (Chapter 2). These activities are 
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part of socio-cultural practices in the Maasai community and make control of animal 
movement very difficult to impose.  
 
Knowledge exchange forms an important part of animal disease control programmes. 
Herders in the study area were aware of clinical signs of CBPP and considered 
vaccination to be the major control method. However, only 27% of herders (48 out of 
175) knew that protection offered by the vaccine lasted for a year at most and only 57% 
(100 out of 175) would like their animals to be vaccinated annually. Therefore, there is 
knowledge gap in herder’s understanding of the duration of protection offered by the 
vaccine and number of vaccinations required to induce “herd immunity”.  Although this 
has not been worked out specifically for CBPP, it is recommended that 100% of animals 
should be vaccinated 3-5 years consecutively (FAO-EMPRES, 1995). Herders 
understanding of the control options (e.g. combination of vaccination and control of 
movement) and their full participation in disease control efforts is therefore important. 
On the other hand, governments should assure or enable availability of affordable 
vaccines and maintenance of surveillance programmes. 
 
Studies on the spatial distribution of infectious diseases such as bovine tuberculosis 
(bTB) have been carried out to understand mechanisms involved in the spread of the 
disease. For infectious diseases, short distance spread is a result of contagion to adjacent 
or nearby farms. This may happen by direct contact and results in local spatial clustering 
(Gilbert et al., 2005). The CBPP cluster identified based on the scan statistic is an 
example of short distance spread of the disease (Chapter 3). Short distance spread could 
have happened for example in herds located near to the water source. Location of herds 
close to the water source was associated with increased risk of being classified as CBPP 
positive (Chapter 3). Hot spots observed during the current study were observed at a 
single point in time. Hot spots may persist or recur or disappear over time as observed 
with bTB data collected over a period between 1986 and 1997 in Great Britain (Pfeiffer 
et al., 2008).  Since the hot spots areas are areas of increased risk, it means that efforts 
could be directed to interrupt disease transmission through targeted disease control 
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programmes. This could be carried out in the form of ring vaccination to create a buffer 
zone. According to OIE regulations, a buffer zone is established to protect animals in a 
free zone/country from those of different health status. This can be carried out through 
measures such as vaccination, quarantine, movement control and surveillance (OIE, 
2008). Unfortunately, due to the inability of the tests to differentiate infected from 
diseased animals, it was not clear if the hot spots in my study were centres of disease or 
centres of vaccination  
 
Control of CBPP based on antibiotic treatment is controversial. There is a suspicion that 
its use could facilitate the developments of sequestra, carrier animals, and resistant 
strains, and that it could mask the occurrence of clinical disease  (Provost et al., 1987). 
In addition, antibiotics were commonly used by herders for a number of conditions 
(Chapter 4). Herders participating in our study shared the opinion that animals treated 
with antibiotic seem to recover but fall sick again after few months. Studies to assess the 
usefulness of antibiotics in the control of CBPP have been reported  (Hübschle et al., 
2006; Twinamasiko et al., 2004; Yaya et al., 2004; Ayling et al., 2000). Findings based 
on animal trials indicated decreased MmmSC transmission to susceptible animals and 
decreased mortality compared to untreated animals. In its fourth meeting, the 
consultative group on CBPP in Africa emphasized the need for further science-based 
evidence on the impact of antibiotic use (FAO, 2006), and reiterated that the use of 
antibiotics is currently not recommended for CBPP control as also stated in the OIE 
Terrestrial Animal Health Code  (Amanfu, 2006).  
 
Vaccination currently remains a better option for CBPP control in pastoral communities 
of East Africa, but it should be used in combination with movement control and 
surveillance. In our study, vaccination was not compared with other control options but 
the majority of herders participating in the study recognized it as the only acceptable 
control method. Rider Haggard in his novel King Solomon’s Mines gives the earliest 
description of field vaccination against CBPP “As of the lung sick which is a dreadful 
form of pneumonia, very prevalent in this country, they had all been inoculated against 
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it. This is done by cutting a slit in the tail of an ox, and binding a piece of the diseased 
lung of an animal which has died of the sickness. The result is that the ox sickens, takes 
the disease in a mild form, which causes its tail to drop off. It seems cruel to rob an 
animal of his tail especially in a country where there are so many flies, but it is better to 
sacrifice the tail and keep the ox than to lose both tail and ox”  (Windsor and Masiga, 
1977). The Maasai herders that participated in our study were aware of the possibility of 
post-vaccination adverse events and indicated that they were successfully managed by 
the use of antibiotics (Chapter 4).  
 
The present PhD work was founded on the findings that use of buffer systems in vaccine 
production and reconstitution improved and prolonged viability of the live MmmSC 
vaccine  (Waite and March, 2001). It was hypothesized that enhanced viability will 
improve vaccine efficacy and possibly result in increased occurrence of adverse events. 
The overall aim of the project was to compare the standard CBPP vaccine and the 
buffered vaccine under field conditions of south-western Kenya. Results of the vaccine 
cohort study show that compared to animals vaccinated with the standard vaccine, 
animals vaccinated with the buffered vaccine had higher odds of developing specific 
adverse events (Chapter 4). The adverse events concentrated in a few herds and a lack of 
previous exposure (CBPP vaccination or outbreak) was observed to be positively 
associated with increased specific events. Additionally, vaccination with buffered 
vaccine was observed to be associated with increased seroconversion; lower odds of 
clinical signs post-vaccination and post ‘outbreak’; and lower seropositivity post 
‘outbreak’ (Chapter 5). Because different outcome parameters were measured in 
different subpopulations, it was not clear that specific events post-vaccination, 
seroconversion or clinical signs of CBPP occurred in the same animals and it is 
unknown whether seroconversion was associated with decreased risk of clinical disease. 
Vaccination with the buffered vaccine was associated with an increase in specific 
adverse event by 15 animals per 10,000; increased seroconversion by 800 animals per 
10,000 vaccinates and a decrease in clinical signs suggestive of CBPP by 3 animals per 
10,000 vaccinates (Chapters 4 and 5). The extent of increase in seroconversion was far 
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greater than the increased adverse events and reduced clinical disease. During this study, 
animals vaccinated with either vaccine were accommodated together and increased 
protection by one vaccine type would have resulted in reduction of disease spread in the 
other group, hence modifying the overall protection difference.  
 
The possibility of vaccination being responsible for the observed clinical signs 
suggestive of CBPP was ruled out because clinical signs were first observed in 
unvaccinated animals that were introduced into the vaccinated herds. CBPP vaccines 
have not been observed to revert to virulence (Wesonga et al., 2004). Clinical disease 
has been observed when vaccine strain was introduced into the lung (Mbulu et al., 
2004). During the current study, vaccine strain was introduced subcutaneously in the tail 
tip (Chapters 4 and 5). Recruitment of an unvaccinated control group was not possible 
due to ethical considerations. An unvaccinated control group would have given baseline 
results for comparison with either vaccine.  
 
6.2 Outlook and future studies 
 
CBPP vaccines currently used in African countries were developed in the 1950’s and 
used as a whole cell vaccine. The information on the specific antigen involved in the 
protection post-vaccination is limited. For example, a study to investigate vaccine 
potential of MmmSC capsular polysaccharide (CPS) has been reported  (Loiselet, 2002). 
The results showed that only a quarter of CBPP vaccinated animals had immune 
responses against CPS. The immune response was of the IgM type even after second 
exposure to the pathogen. The lack of an immune response was linked to cross reaction 
of CPS with bovine lung antigens. This finding could possibly explain the small 
percentage of animals that seroconverted post vaccination. Recent studies to characterize  
MmmSC- specific humoral responses with sera and bronchial lavage fluid (BAL) taken 
from experimentally infected animals indicated that IgA levels were high both in sera 
and BAL samples and tended to persist in subacute and chronic forms of disease (Niang 
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et al., 2006). The IgA proteins offer the potential for developing a mucosal vaccine. 
“Mucosal vaccine could offer the benefit from the existence of a ‘common mucosal 
immune system’ where immunization at some mucosal inductive sites can activate 
mucosal B-and T-cells to migrate from these sites and home to mucosal effector cells” 
(Dedieu-Engelmann, 2008). Another study was conducted to investigate vaccine 
delivery efficiency using immunostimulating complex (ISCOM). Use of the vaccine in 
combination with this adjuvant showed reduced mortality post challenge compared to 
unvaccinated controls  (Hübschle et al., 2003). The studies cited here and the results 
from my study indicate that progress has been made but there is a need to identify 
specific antigens responsible for protection post-vaccination and possibly for 
improvement of the vaccine delivery efficiency. Such studies may open the way to the 
development of DIVA vaccines. Development of a DIVA vaccine has also been 
recommended by the third meeting of the Consultative group on CBPP in Africa (FAO, 
2004). Development of a DIVA vaccine needs to be accompanied by the improvement 
of diagnostic tests. Proteomic studies have indicated a number of immunogens 
recognized by pooled sera from experimentally infected animals. These proteins may 
have potential for the development of CBPP diagnostic tests (Jores et al., 2009).  
 
Maasai herders were aware of the poor safety associated with CBPP vaccines and the 
outcome of the current study was no exception. As part of the Wellcome Trust funded 
project on CBPP, a scientific evaluation of perceptions and costs and benefits of use of 
buffered vaccine is underway based on socioeconomic data analysis. Our study has 
given an indication that vaccination with the buffered vaccine offered better protection 
but poorer safety than vaccination with the standard vaccine. The finding stresses a need 
to give vaccine safety due consideration when developing more efficacious CBPP 
vaccines. 
 
Vaccine handling under field conditions has been suggested to influence the vaccination 
outcome (safety and efficacy)  (Karimuribo et al., 1997). In our study, vaccine handling 
under field conditions was monitored through vaccine use time and cool box 
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temperature and it was observed that reconstituted vaccines were sometimes kept 
beyond recommended time and temperature. There is a need therefore to carry out 
quantitative analysis of vaccine titre for vials kept in various temperature conditions post 
reconstitution. This analysis would allow an exploration of whether buffering provides a 
longer ‘window of use’ under field conditions, where infrastructure does not allow 
vaccine to be used within 2 hours and to be kept at ≤4˚C. Evaluation of Xerovac process 
for preparation of heat tolerant CBPP vaccine has been reported (Litamoi et al., 2005). 
The process involves dehydration of vaccine via careful maintenance of high pressure at 
the product surface. Further studies were suggested to optimize vaccine culture 
procedures and the actual xerovac dehydration technique. 
  
 The Narok and Naroosura teams used in the current study represented public and 
private teams respectively. Comparison of public and private teams was not given 
priority because each partner was represented by only one team. Generally, it was 
observed that the teams worked very similar and, as a parameter, team had no 
modification effect on the vaccine efficacy. Decentralization of veterinary services 
compounded by limited extension services and cost recovery approaches has resulted 
into poor access to vaccines by rural communities of developing countries (Lubroth et 
al., 2007).  The use of private partnership in CBPP vaccine delivery could be assessed 
and complement vaccine delivery by government teams in the rural areas.  
 
The current trial was carried out in Maasai ecosystem of south-western Kenya, which 
might be representative of the Maasai ecosystem of Serengeti and Ngorongoro areas of 
the United Republic of Tanzania. However because of variation in cattle breeds and 
management systems in pastoral systems of Africa there is a need to explore further their 
influence. Also, there is need to explore further the role of trypanosomosis in the control 
of infectious diseases such as CBPP.  
 
The scan statistic test proved to be a useful method for identifying CBPP ‘hot spots’. 
Disease hot spot detection may have great value in disease control therefore a need to 
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carry out pilot studies to identify and asses the usefulness of targeted CBPP control 
strategies  in CBPP ‘hot spots’.  
 
In summary therefore, my study reinforces the need for better tools for CBPP control. 
Availability of safe and efficacious vaccines is of urgent importance. Vaccination should 
be carried out in combination with other strategies such as movement control and 
surveillance. Surveillance will require diagnostic tests that can confirm presence of the 
disease (increased sensitivity) or rule out the disease (increased specificity), even when 
vaccination is used in the population that is surveyed. Educating herders about the 
access, use and limitation of CBPP vaccines and their shared responsibility in CBPP 
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Appendix i: Cross sectional study questionnaire 
 
SERIAL NUMBER …….. Enumerator code---------------------------Date of interview---------/-------/ 2006  Boma ID ------------ 
START TIME ……………….... END TIME………………....  
 
 
SECTION A: GENERAL 
A1 Name of household Head surname ……………………other name……………………. 
A2  Respondent’s name surname ……………………other name……………………. 
A3 Sex of respondent: ……. A4  Age set of respondent…………… (yrs) A5 Division: ………………………… 
A6 Location……………………………………..A7 Sub location…………………………………….  
A8 Village name………………………………  




















SECTION B: CATTLE DISEASES 




 B2 Rank the 5 most important cattle diseases/conditions and give the criteria for ranking. 
  (1 is most important and 5 is least important) 
 
 
B3 Do you know CBPP? Y=Yes N=No (ask this question only if CBPP is not mentioned in B1, otherwise go to B5 if No proceed to 
section C) 
B4 What are the clinical symptoms and post mortem lesions of CBPP? (can mention at least 6 of each, PLEASE DO NOT 
PROMPT)  
 Clinical signs Post-mortem lesions 
1   
2   
3   
4   
5   
6   
 Disease Criteria 
1   
2   
3   
4   
5   
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B5 In which year (s) did you have CBPP in your herd?, how many were affected, died or recovered, what was the duration 
of the clinical disease, cause of disease and how many animals did you have then, what did you do  













































































































































































2005  [     ]    [     ]  [     ]  [    ]  
2004  [     ]    [     ]  [     ]  [    ]  
2003  [     ]    [     ]  [     ]  [    ]  
2002  [     ]    [     ]  [     ]  [    ]  
2001  [     ]    [     ]  [     ]  [    ]  
2000  [     ]    [     ]  [     ]  [    ]  
1999  [     ]    [     ]  [     ]  [    ]  
 
Duration of clinical disease Reasons for recovery Interventions Other costs 
1=<3 months 1=treatment 1=treatment 1=additional labour 
2=3-6 months 2=vaccination 2=vaccination 2=time 
3=7-12 months 3=other 3=traditional quarantine 3=travel costs 
4=>12 months  4=government 
quarantine 
4=other (specify) 
5= I don’t know  5=slaughter  
  6=report to vet office  
  7=other (specify)  
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B6 Are there cattle that have suffered the disease more than once in your herd? Y=YesN=No  (ask farmers that had 
experienced CBPP) 
B7 What was the estimated time between any two episodes?  
1=up to 6months       
2=between 7-12 months     
3=more than 13 months 
B8 Are there neighbours that had experienced CBPP in their herds? Y=Yes N=No 
B9 From which villages? 1………………….2……………………3…………………….. 
B10 Do you treat animals suffering from CBPP? Y=Yes N=No (if No go to B18) 
B11 What type of medicine do you use, route of administration, dosage, duration of treatment and rate of recovery?  
Drug route of administration dosage duration of treatment rate of recovery (out of 10) 
     
     
Drug route of administration 
1=terramycin 10% 1=intramuscular 
2= terramycin 20% 2=intrapleural 
3=terramycin 30% 3=Other (specify) 
4=Olchani oiborr  
5=Other (specify)  
 
B12 Is the treatment effective? Y=Yes N=No  
Explain................................................................................................................................................................................................ 
B13 Do the animals recovered with treatment become sick of CBPP again? Y=Yes N=No     
B14 How long does it take for treated animal to fall sick again? 
1=up to2 months  
2=3 – 6 months 
3= 7-12 months 
4=>12 months  
B15 Are there animals that recover without treatment? Y=Yes N=No 











B17 Do you have your cattle vaccinated? Y=Yes N=No (Please indicate cattle vaccinations for the last 12 months) 











≤1 year 1-3 years ≥3 years  
 [     ]  [     ]     
 [     ]  [     ]     
 [     ]  [     ]     
Who vaccinated Vaccine source 
1=self 1=Private vet 
2=government vets 2= Narok Veterinary Office 
3=private vet 3=Kabete 
 4=NGO 
 5=Other (specify) 
 
B18 If CBPP not mentioned in B20, Ask:Do you have your cattle vaccinated against CBPP Y=Yes; N=No 
B19 In which year did you have your animals vaccinated against CBPP, why, how many, which ages, at what total cost? 
(Enter  for all Years, Yes or No and record reasons) 
Year 
(months) 
Y=Yes;N=No Reasons for vaccinating/  
not vaccinating 
How many  Ages  Total cost 
2006 [     ] [     ]  [     ]  
2005 [     ] [     ]  [     ]  
2004 [     ] [     ]  [     ]  
2003 [     ] [     ]  [     ]  
2002 [     ] [     ]  [     ]  
2001 [     ] [     ]  [     ]  
2000 [     ] [     ]  [     ]  
1999 [     ] [     ]  [     ]  
      
Reasons for vaccinating Reasons for not vaccinating Ages vaccinated 
1=routine 1= fear of severe reactions 1=<1year 
2=rumour 2=expensive 2=1-3years 
3=outbreak within herd 3=fear reduced productivity 3=>3years 
4=ring vaccination 4=preferred to do something else 4=All 






B20 Are there vaccinated animals that had CBPP? Y=Yes N=No  
Which year and how many? 
Age 2006 2005 2004 2003 2002 2001 2000 1999 
 No. sick No. sick No. sick No. sick No. sick No. sick No. sick No. sick 
<1 
year 
        
1-3 
years 
        
>3 
years  
        
 




4=> 12 months  
 
B22 How often would you like your cattle vaccinated against CBPP? 
1=once a year  why?................................................................ 
2=twice per year why?................................................................ 
3=other, specify why?................................................................ 
 
B23 Did cattle have any problems associated with the vaccination? Y= Yes N=No   
If Yes; what kind of problems and how many out of 10 
Year Type of reaction No. out of 10 
  1 2 3 4 5 6 7 
2006 [  ,   ,   ]        
2005 [  ,   ,   ]        
2004 [  ,   ,   ]        
2003 [  ,   ,   ]        
2002 [  ,   ,   ]        
2001 [  ,   ,   ]        
2000 [  ,   ,   ]        
1999 [  ,   ,   ]        
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Type of reaction 
1= Slough off tail     
2= Swelling at injection site    
3=Death       
4= Abortions      
5= Weakening of animals     
6= Drop of milk production    
7=Others (specify)……………………………………………………………………………………   
 
B24 Do the neighbours vaccinate against CBPP? Y=Yes N=No  
 
 
SECTION C: HERD DATA 










C2 What are the cattle herd sizes in the other households within the boma? 
Name of household 
head 









C3 Among the cattle, what have been the changes over the last 12 months?  






















































































































































                 
1-
3years  
                 
>3 
years  







Reasons for sales Reasons for 
loans 
Reasons for gifts 
1=Disease 1=Disease 1=Restocking 1=cash 1=ploughing 1=Friendship 





3=still birth 3=household use 3=build herd 3=disease (specify) 3=milk 3=dowry 
4=predation 4=ceremony 4=for fattening 4=Other (Specify) 4=restocking 4=Other (specify) 





6=Drought 6=Other (specify)     
7=Other 
(specify) 





C4 Where did animals go for watering, grazing and salt licks in the last 12 months?  
 (ask the farmers to mention maximum of three places including close and far places) 
 Watering points Grazing places Salt lick points 
Village name …………… Village name …………… Village name …………… 
Village name …………… Village name …………… Village name …………… 
Dry 
season 
Village name …………… Village name …………… Village name …………… 
Village name …………… Village name …………… Village name …………… 
Village name …………… Village name …………… Village name …………… 
Wet 
season 
Village name …………… Village name …………… Village name …………… 
 
C5 Did your animals mix with others at watering points? Y=Yes N=No; Grazing Y=Yes N=No; Saltlicks Y=Yes N=No  
 
C6  What is the level of mixing at the common watering, Salt licks and grazing points?  
 Watering points Grazing places Salt lick points 
Dry season Level of mixing ………… Level of mixing ………… Level of mixing ………… 
Wet season Level of mixing ………… Level of mixing ………… Level of mixing ………… 
Fill in  1=completely mixed  
2=No mixing at all 
3=Partially  
 
C7 Estimate number of herds that mix with at water, grazing and salt lick points.  
 (ask the farmers to give an estimate of minimum and maximum number of herds) 
 Watering points Grazing places Salt lick points 
Dry 
season 
Number of herds 
…………………... 
Number of herds 
…………………... 




Number of herds 
…………………... 
Number of herds 
…………………... 













C8 Where do herds that mix with at water, grazing and salt lick points come from?  
 (ask the farmers to mention maximum of three places including close and far places) 
 Watering points Grazing places Salt lick points 
Village name 
…………………... 




























C9 At which markets do you normally sell animals?............................................................................................... 
 
Market Why this market Origin of animals at the market 
(close and far places) 
 [ , , ] ……………………… 
……………………… 
……………………… 
 [ , , ] ……………………… 
……………………… 
……………………… 
 [ , , ] ……………………… 
……………………… 
……………………… 
 [ , , ] ……………………… 
……………………… 
……………………… 
 [ , , ] ……………………… 
……………………… 
……………………… 
 [ , , ] ……………………… 
……………………… 
……………………… 




C10 Do you bring back animals that did not fetch market? Y=Yes N=No 
C11 From which markets do you bring back animals?.............................,………………………,………………………. 
 
C12 How are the animals accommodated during the night, how many herds and where from? 
 Number of herds Where from  
…………………... Village name …………………......................... 
…………………... Village name …………………......................... 
Dry season 
…………………... Village name …………………......................... 
…………………... Village name …………………......................... 
…………………... Village name …………………......................... 
Wet season 
…………………... Village name …………………......................... 
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Appendix ii: Message detailing vaccination programme to herders 
 
                                                                                                         
 
 
WELLCOME TRUST PROGRAM FOR CBPP VACCINATION IN OSUPUKO, LOITA AND 
MARA DIVISIONS OF NAROK DISTRICT 
 
• There will be a free vaccination campaign against CBPP which is a common 
problem among our cattle from 5
th
 January – 26
th
 March 2007.  
 
• The Moredun Research Institute (UK) has developed a new vaccine which we 
hope will offer protection longer than the current CBPP vaccine so both vaccines will be 
used concurrently. 
 
• This vaccination campaign is being funded by Wellcome Trust (UK) and 
coordinated by DVO-Narok and VSF-Germany. VSF-Germany has also introduced the well 
known E.C.F vaccine. 
 
• After vaccination the herds will be monitored by Research Scientists from ILRI 
and KARI together with yourselves and our Community-based animal health workers for 1 
year. 
 
• We urge you to present your cattle of over one month of age to be vaccinated so 
as to get rid of this disease to allow us to sell our cattle to KMC and other livestock 
markets locally and internationally. 
 





Appendix iii: Contagious bovine pleuropneumonia vaccination form 
                                                                                                          
Herder’s Name……………………Village/Cluster (s) ....................Crush name.................... 
sub location ....................location ....................Division....................Date.................... 
Vaccination Team  Narok team /Naroosura team 
 Animal ID  







Age  Body condition Batch No Time  
1     Good/Fair/poor   
2     Good/Fair/poor   
3     Good/Fair/poor   
4     Good/Fair/poor   
5     Good/Fair/poor   





Appendix iv: Contagious bovine pleuropneumonia bleeding form 
 
Date: 
Farmer’s Name………………………………. Year of last CBPP Vaccination.................... 





 Animal ID  
 (Ear tag No) 
Other identifier 
Tail tip  
measure (cm) 
other treatment /vaccination/remarks  
 
1.   OTC, Veriben, Levamisole,…………. 
2.   OTC, Veriben, Levamisole,…………. 
3.   OTC, Veriben, Levamisole,…………. 
4.   OTC, Veriben, Levamisole,…………. 
5.   OTC, Veriben, Levamisole,…………. 
6.   OTC, Veriben, Levamisole,…………. 
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Appendix v: Contagious bovine pleuropneumonia monthly monitoring form 
                                                                                                                                                                         
 
Herder’s name………………………… ….Cluster/village....................Crush name....................Month.................... 
















Signs (if died then 
signs prior to death) 
Drug (s) or vaccine 
administered and 
dose 
1.        
2.        
3.        
4.        
5.        
…        
Type of events 
1=Died 2=Sold 3=Gifts in/out 4=Diseased 
 
5=Loans in/out  6=purchased 7=Births 8= Other …… 
eg. abortion 
Reasons for deaths Reasons for sales Reasons for gifts Disease  Reasons for loans Reasons for 
purchases 
 Reason  
1=Disease 1=cash 1=Friendship 1=Olkipiei  1=ploughing 1=Restocking  …...................
. 
2=Age 2=poor performance 2=ceremony 2=Ntorobo 2=breeding 2=Improve breed  …...................
. 
3= predation  3=disease (specify) 3=dowry 3=Olkirobi 3=milk 3=build herd  …...................
. 
4=Unknown 4=Other (Specify) 4=Other (specify) 4=Oltikana 4=restocking 4=for fattening  …...................
. 
5=other (specify) …........................ ….................... 5=Other (specify 5=Other (specify) 5=Other (specify)  …...................
. 




Appendix vi: Multivariable linear logistic mixed model based on specific adverse events 
 
a) Logit  (p)=β0+ VaccinetypeB+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 24.26 1 24.26 79908.3 <0.001 
 
Standard  0.001902 
Buffered 0.002781 
 
b) Logit (p)=β0+ VaccinetypeB+AgeA+ VaccinetypeB *AgeA+ bj + ε 
Fixed term  Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 21.78 1 21.78 79890.6 <0.001 
Agecat 3.00 1 3.00 78030.8  0.083 
VaccinetypeB*Age 8.39 1 8.39 79906.1  0.004 
 
 Young animals Adult animals 
Standard  0.002686 0.001716 
Buffered 0.002657 0.002845 
bj Random term  (crush and herd) 
ε Error term 
 
c) Logit (p)=β0+ VaccinetypeB +Teamsura + VaccinetypeB *Teamsura+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 23.50 1 23.50 79904.6 <0.001 
Teamsura 0.07 1 0.07 17.2  0.793 
Vaccinetype* Teamsura 6.99 1 6.99 79906.5  0.008 
 
 Narok Naroosura 
Standard 0.001544 0.002233 
Buffered  0.002835 0.002715 
 
d) Logit (p)=β0+ VaccinetypeB + Gender F + VaccinetypeB * Gender F + bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 26.47 1 26.47 79890.8 <0.001 
Gender F 16.56 1 16.56 79927.3 <0.001 
Vaccinetype*Gender 4.58 1 4.58 79762.1  0.032 
 
 Male Female 
Standard 0.001717 0.001986 
Buffered 0.001899 0.003183 
 
e) Logit (p)= β0+ VaccinetypeB +DivisionMO + VaccinetypeB * DivisionMO + bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 20.63 1 20.63 79904.4 <0.001 
DivisionMO 6.79 2 3.40 20.5  0.053 
Vaccinetype*Division 18.18 2 9.09 79916.2 <0.001 
 
 Loita Mara Osupuko 
Standard 0.001063 0.001020 0.004578 




Appendix vii: Multivariable linear logistic mixed model based non-specific adverse events  
 
a) Logit  (p)=β0+ VaccinetypeB+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.13 1 0.13 79895.6 0.716 
  
Standard  0.0010022 
Buffered 0.0009692 
 
b) Logit (p)=β0+ VaccinetypeB+AgeA+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.14 1 0.14 79901.7  0.707 
AgeAdult 34.26 1 34.26 77731.7 <0.001 
 
Standard  0.001153 
Buffered 0.001115 
  
Young animals 0.001524 
Adult animals 0.000844 
 
c) Logit (p)=β0+ VaccinetypeB + BodyFair+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.13 1 0.13 79899.1  0.714 
BodyFair 9.38 1 9.38 61492.7  0.002 
 






d) Logit (p)= β0+ VaccinetypeB +DivisionMO + VaccinetypeB * DivisionMO + bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.11 1 0.11 79884.4  0.737 
division 2.76 2 1.38 16.9  0.278 
Vaccinetype*Division 5.53 2 2.77 79917.0  0.063 
 
 Loita Mara Osupuko 
Standard 0.0006818 0.0013544 0.0009863 





Appendix viii: Multivariable linear logistic mixed model based antimicrobial treatment 
 
a) Logit  (p)=β0+ VaccinetypeB+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 3.57 1 3.57 79888.7 0.059 
 
Standard  0.008815 
Buffered 0.009723 
 
b) Logit (p)=β0+ VaccinetypeB+AgeA+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 2.93 1 2.93 79873.5  0.087 
AgeAdult 17.05 1 17.05 78318.1 <0.001 
Vaccinetype*Age 3.39 1 3.39 79878.4  0.066 
 
 Young animals Adult animals 
Standard  0.01167 0.00809 
Buffered 0.01088 0.00940 
 
c) Logit (p)=β0+ VaccinetypeB + BodyFair+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 3.57 1 3.57 79889.0  0.059 
BodyFair 6.33 1 6.33 74021.3  0.012 
 








Appendix ix: Detailed outbreak investigation: multivariable linear logistic mixed model based on 
clinical signs 
 
a) Logit  (p)= β0+ VaccinetypeB+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB  0.44 1 0.44 288.1  0.505 
 
Standard  0.05368 
Buffered 0.03976 
 
b) Logit  (p)=β0+ VaccinetypeB+AgeA+ VaccinetypeB *AgeA+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.52 1 0.52 286.3  0.473 
AgeA 0.45 1 0.45 287.4  0.503 
VaccinetypeB*AgeA 0.51 1 0.51 287.0  0.474 
  
 Young animals Adult animals 
Standard  0.08012 0.04261 
Buffered 0.03871 0.04064 
 
c) Logit  (p)= β0+ VaccinetypeB + Gender F + VaccinetypeB * Gender F + bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.95 1 0.95 286.4  0.330 
Gender F 4.96 1 4.96 288.0  0.027 
VaccinetypeB*Gender F 1.01 1 1.01 286.2  0.316 
  
 Male Female  
Standard  0.14310 0.03095 
Buffered 0.06085 0.03385 
 
d) Logit  (p)= β0+ VaccinetypeB + BodyFair+ VaccinetypeB*BodyFair+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 0.52 1 0.52 286.1  0.471 
BodyFair 0.06 1 0.06 288.4  0.804 
VaccinetypeB*BodyFair 0.78 1 0.78 286.1  0.378 
  
  
 Good Fair  
Standard  0.06276 0.02731 




Appendix x: Vaccination subset: Multivariable linear logistic mixed model based on 
seroconversion data 
 
a) Logit  (p)= β0+ VaccinetypeB+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 15.73 1 15.73 1797.2 <0.001 
 
Standard  0.2738 
Buffered 0.3616 
 
b) Logit  (p)= β0+ VaccinetypeB+AgeA+ VaccinetypeB *AgeA+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 15.80 1 15.80 1795.9 <0.001 
AgeA 2.20 1 2.20 1780.1  0.138 
VaccinetypeB *AgeA 0.72 1 0.72 1797.8  0.398 
 
 Young animals Adult animals 
Standard  0.2637 0.2791 
Buffered 0.3236 0.3834 
 
c) Logit  (p)= β0+ VaccinetypeB + Gender F + VaccinetypeB * Gender F + bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 15.59 1 15.59 1795.1 <0.001 
Gender F 5.55 1 5.55 1810.4  0.019 
VaccinetypeB * Gender F 0.00 1 0.00 1791.0  0.948 
 
  Male Female  
Standard  0.2353 0.2894 
Buffered 0.3208 0.3811 
 
d) Logit  (p)= β0+ VaccinetypeB + BodyFair+ VaccinetypeB*BodyFair+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 16.04 1 16.04 1795.9 <0.001 
BodyFair 6.05 1 6.05 1522.4  0.014 
VaccinetypeB*BodyFair 1.96 1 1.96 1807.5  0.162 
 
  Good Fair  
Standard  0.2787 0.2360 
Buffered 0.3818 0.2352 
 
e) Logit  (p)= β0+ VaccinetypeB +DivisionMO + VaccinetypeB * DivisionMO + bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 15.40 1 15.40 1794.8 <0.001 
DivisionMO 3.33 2 1.66 9.9  0.238 
VaccinetypeB * DivisionMO 1.61 2 0.81 1794.4  0.446 
 
vaccinetype LOITA  MARA OSUPUKO 
Standard  0.2507 0.3483 0.2213 






f) Logit  (p)= β0+ VaccinetypeB +Teamsura + VaccinetypeB *Teamsura+ bj + ε 
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 15.59 1 15.59 1796.2 <0.001 
Teamsura 3.13 1 3.13 11.0  0.104 
VaccinetypeB *Teamsura 0.68 1 0.68 1796.6  0.411 
 
  Narok Naroosura 
Standard  0.3038 0.2454 




Appendix xi: Detailed outbreak investigation: Multivariable linear logistic mixed model based on 
seroprevalence 
 
f) Logit  (p)=β0+ VaccinetypeB+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB  2.90 1 2.90 288.9  0.090 
 
Standard  0.2161 
Buffered 0.1338 
 
g) Logit  (p)= β0+ VaccinetypeB+AgeA+ VaccinetypeB *AgeA+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 2.03 1 2.03 286.6  0.155 
AgeA 3.02 1 3.02 287.1  0.083 
VaccinetypeB*AgeA 1.74 1 1.74 286.9  0.188 
  
  Young animals Adult animals 
Standard  0.1853 0.2308 
Buffered 0.0547 0.1819 
 
h) Logit  (p)= β0+ VaccinetypeB + Gender F + VaccinetypeB * Gender F + bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 2.83 1 2.83 286.8  0.093 
Gender F 0.04 1 0.04 287.1  0.846 
VaccinetypeB*Gender F 0.13 1 0.13 286.1  0.714 
  
 Male Female  
Standard  0.2232 0.2138 
Buffered 0.1142 0.1408 
 
i) Logit  (p)= β0+ VaccinetypeB + BodyFair+ VaccinetypeB*BodyFair+ bj + ε  
Fixed term Wald statistic n.d.f. F statistic d.d.f. F pr 
VaccinetypeB 2.54 1 2.54 286.9  0.112 
BodyFair 4.26 1 4.26 287.3  0.040 
VaccinetypeB*BodyFair 0.12 1 0.12 286.2  0.726 
  
 Good Fair  
Standard  0.2486 0.1223 
Buffered 0.1605 0.0539 
 
